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ABSTRACT 
 
Investigation of Novel Tumor Markers  
Based On Hybridoma Technology  
Hilal Çelikkaya 
 
M.Sc. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Tamer Yağcı 
2004, 75 Pages 
 
Hybridoma technology is a highly specific technique utilized for the production of 
monoclonal antibodies. In cancer research, monoclonal antibodies are used as tumor 
markers for diagnosis of malignant tissue versus benign or normal, for differential 
diagnosis of tumor type, for pathological grading of tumor biopsy specimens, for 
detection of the antigens that are up- or down-regulated in tumor cells or in sera of 
cancer patients, and for detection of primary or metastatic lesions. Additionally, 
monoclonal antibodies are employed in predicting the course of the disease, in 
diagnostic approaches for carrying imaging reagents to tumors, and in therapy for 
targeting cytotoxic reagents to and triggering or blocking cell surface molecules. This 
study involved generation of 6D5 and 9C11 monoclonal antibodies against apoptosis 
induced hepatocellular carcinoma cell line HuH-7, followed by characterization 
experiments. 6D5 antibody recognized 5 different epitopes in a panel of 28 cell lines in 
Western blotting experiments. In immunohistochemistry studies, 6D5 demonstrated 
positive staining in cirrhotic and cancerous cells of liver cancer tissue samples. On the 
other hand, 9C11 antibody recognized a single band in the same panel of 28 cell lines 
but it was not immunoreactive in immunoperixodase studies of liver cancer tissue 
samples, under our experimental conditions.   
 III
ÖZET 
 
Yeni Tümör Belirleyicilerin 
Hibridoma Teknolojisine Dayalı Olarak Araştırılması 
Hilal Çelikkaya 
 
Yüksek Lisans Tezi, Moleküler Biyoloji ve Genetik Bölümü 
Tez Yöneticisi: Yard. Doç. Tamer Yağcı 
2004, 75 Sayfa 
 
Hibridoma teknolojisi, monoklonal antikor üretimi için yararlanılan oldukça özgün bir 
tekniktir. Monoklonal antikorlar kanser araştırmalarında; kanserli dokunun benign veya 
normal dokuya karşı ayırıcı tanısında, tumor tipinin ayırıcı tanısında, tumor biyopsisi 
örneklerinin evrelerinin belirlenmesinde, tumor hücreleri veya kanserli hasta 
serumlarında artan veya azalan biçimde düzenlenen antijenlerin saptanmasında ve 
birincil veya metastazik lezyonların saptanmasında tumor belirleyici olarak 
kullanılmaktadır. Bunun yanı sıra monoclonal antikorlar; hastalık seyrinin öngörüsünde, 
görüntüleme ayıraçlarının tumor hücrelerine hedeflenmesi gibi tanısal yaklaşımlarda ve 
terapide, sitotoksik ayıraçların hücre yüzey moleküllerine yönlendirilmesi ve hücre 
yüzey moleküllerinin tetiklenmesi veya bloke edilmesi icin kullanılmaktadır. Bu 
çalışma, apoptoz tetiklenmiş hepatoselüler karsinom hücre hattı HuH-7’a karşı 6D5 ve 
9C11 monoklonal antikorlarının üretimini takiben, karakterizasyon deneylerini 
içermektedir. 6D5 antikoru, Western blotlaması deneylerinde kullanılan 28 hücre 
hattından oluşan bir panelde 5 farklı epitopu tanımaktadır. Immünohistokimya 
çalışmalarında 6D5, karaciğer kanseri doku örneklerindeki sirozlu ve kanserli hücreleri 
pozitif  boyamaktadır. Diğer yandan, 9C11 antikoru, 28 hücre hattından oluşan aynı 
panelde tek bir bant tanımakta ancak kullandığımız deneysel koşullar altındaki 
immunohistokimya çalışmalarında,  karaciğer kanseri doku örneklerinde 
immunoreaktivite göstermemektedir. 
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1. INTRODUCTION 
 
1.1. Understanding Cancer 
 
Among the 75 to 100 trillion of an estimated number of cells in the human body, it is 
not surprising that one or some of our cells may gain an aberrant proliferative 
activity in the course of a lifetime. Beyond this, any individual may contain 
hereditary defects leading to abnormal proliferative activity of her/his cells. 
However, not every aberrant proliferation of cells is referred to as cancer. Excessive 
division of the cells gives rise to an abnormal mass of tissue, called tumor or 
neoplasm. If the cells of the tumor stay clustered together in this tumor mass without 
spreading to surrounding tissue or farther, the neoplasm is said to be benign. On the 
contrary, malignant (cancerous) tumors invade the nearby tissue and metastasize to 
distant parts of the body (American Cancer Society, 2004; Alberts et al., 2002; 
DeVita et al., 2001; http://www.nci.nih.gov).  
 
 
1.2. Cancer Incidence and Mortality Rates 
 
In American population, the lifetime risk of a male individual of developing cancer is 
nearly 1 in 2 and it is nearly 1 in 3 for females. American Cancer Society states that 
about 1,368,030 new cancer cases are expected to be diagnosed in 2004 in the United 
States (U.S.) excluding carcinoma in situ of any site except urinary bladder and 
cancers of basal and squamous cells of skin (Table 1.1). The estimated number of 
basal and squamous cell skin cancers in 2004 is more than one million (American 
Cancer Society, 2004). 
 
According to National Vital Statistics Reports of leading causes of deaths for 2001 
(Arias et al., 2001), malignant neoplasms rank in the second order coming after the 
diseases of heart as being the first cause of deaths during 2000-2001 in the U.S. 
Malignant neoplasms are still ranking in the second place in the published 
preliminary data of National Vital Statistics Reports for the year 2002. The 
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estimation of American Cancer Society for 2004 reaches a consensus on ranking of 
cancer deaths with those previous reports. As a result, every year, 1 of every 4 people 
in the U.S. dies of cancer. 563,700 cancer deaths are expected to occur in U.S. in 
2004, which means more than 1,500 people dying of cancer per day (American 
Cancer Society, 2004). 
 
 
1.3. Cancer Development 
 
It should be noted that anyone can develop cancer. There is a diverse set of genomic 
abnormalities in cancer cells and those abnormalities affect the phenotype of those 
cells as well. Loss of differentiation, increased motility leading to invasion and 
metastasis, deregulation of cell cycle control, self-sufficiency in growth signals, 
escape from apoptosis, sustained angiogenesis and decreased drug sensitivity are 
among the significant characteristics of cancer cells. As DeVita et al. (2001) 
underlines, there is a common misconception such as “cancer cells replicate faster 
than their normal counterparts”. However, the growth abnormality of cancer cells is 
not a result of faster replication but lack of cell cycle control and insensitivity to anti-
growth and apoptotic signals. Understanding the interconnections between growth 
inhibitory and growth stimulatory pathways would reveal the complexity of cell 
growth control networks. 
 
The progression of cancer from a normal tissue is a multistep process and it takes 
place between 5 to 20 years. During the years of cancer progression, accumulation of 
mutations occurs resulting in malignant phenotype and this suggests that genetic 
instability is an early occurring event during tumor progression. Despite this fact, the 
exact number of mutations leading to malignancy is not known.  Cancer progression 
is influenced by both inherited factors and somatic genetic changes, which is affected 
by both intrinsic (hormones, immune conditions, mutations occurring as a result of 
metabolic activity) and extrinsic factors (tobacco, chemicals, radiation, infectious 
organisms). About 5% to 10% of cancers are caused by hereditary defects.  
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Table 1.1: Estimated new cancer cases and deaths by sex for all body sites, U.S., 
2004* (taken from American Cancer Society, 2004) 
 
Estimated New Cases Estimated Deaths 
 Both Sexes Male Female Both Sexes Male Female 
All sites 1,368,030 699,560 668,470 563,700 290,890 272,810 
Oral cavity & pharynx 28,260 18,550 9,710 7,230 4,830 2,400 
   Tongue 7,320 4,860 2,460 1,700 1,100 600 
   Mouth 10,080 5,410 4,670 1,890 1,070 820 
   Pharynx 8,250 6,330 1,920 2,070 1,460 610 
   Other oral cavity 2,610 1,950 660 1,570 1,200 370 
Digestive system 255,640 135,410 120,230 134,840 73,240 61,600 
   Esophagus 14,250 10,860 3,390 13,300 10,250 3,050 
   Stomach 22,710 13,640 9,070 11,780 6,900 4,880 
   Small intestine 5,260 2,750 2,510 1,130 610 520 
   Colon† 106,370 50,400 55,970 56,730 28,320 28,410 
   Rectum 40,570 23,220 17,350    
   Anus, anal canal & anorectum 4,010 1,890 2,120 580 210 370 
   Liver & intrahepatic bile duct 18,920 12,580 6,340 14,270 9,450 4,820 
   Gallbladder & other biliary 6,950 2,960 3,990 3,540 1,290 2,250 
   Pancreas 31,860 15,740 16,120 31,270 15,440 15,830 
   Other digestive organs 4,740 1,370 3,370 2,240 770 1,470 
Respiratory system 186,550 102,730 83,820 165,310 95,460 69,670 
   Larynx 10,270 8,060 2,210 3,830 3,010 820 
   Lung & bronchus 173,770 93,110 80,660 160,440 91,930 68,510 
   Other respiratory organs 2,510 1,560 950 860 520 340 
Bones & joints 2,440 1,230 1,210 1,300 720 580 
Soft tissue (including heart) 8,680 4,760 3,920 3,660 2,020 1,640 
Skin (excluding basal & squamous) 59,350 31,640 27,710 10,250 6,590 3,660 
   Melanoma 55,100 29,900 25,200 7,910 5,050 2,860 
   Other nonepithelial 4,910 2,400 2,510 2,340 1,540 800 
Breast 217,440 1,450 215,990 40,580 470 40,110 
Genital system 323,210 240,660 82,550 59,250 30,530 28,720 
   Uterine cervix 10,520  10,520 3,900  3,900 
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   Uterine corpus 40,320  40,320 7,090  7,090 
   Ovary 25,580  25,580 16,090  16,090 
   Vulva 3,970  3,970 850  850 
   Vagina & other genital, female 2,160  2,160 790  790 
   Prostate 230,110 230,110  29,900 29,900  
   Testis 8,980 8,980  360 360  
   Penis & other genital, male 1,570 1,570  270 270  
Urinary system 98,400 68,290 30,110 25,880 17,060 8,820 
   Urinary bladder 60,240 44,640 15,600 12,710 8,780 3,930 
   Kidney & renal pelvis 35,710 22,080 13,630 12,480 7,870 4,610 
   Ureter & other urinary organs 2,450 1,570 880 690 410 280 
Eye & orbit 2,090 1,130 960 180 110 70 
Brain & other nervous system 18,400 10,540 7,860 12,690 7,200 5,490 
Endocrine system 25,520 6,950 18,570 2,440 1,440 1,300 
   Thyroid 23,600 5,960 17,640 1,460 620 840 
   Other endocrine 1,920 990 930 980 520 460 
Lymphoma 62,250 33,180 29,070 20,730 11,090 9,640 
   Hodgkin disease 7,880 4,330 3,550 1,320 700 620 
   Non-Hodgkin lymphoma 54,370 28,850 25,520 19,410 10,390 9,020 
Multiple myeloma 15,270 8,090 7,180 11,070 5,430 5,640 
Leukemia 33,440 19,020 14,420 23,300 12,990 10,310 
   Acute lymphocytic leukemia 3,830 2,110 1,720 1,450 820 630 
   Chronic lymphocytic leukemia 8,190 5,050 3,140 4,800 2,730 2,070 
   Acute myeloid leukemia 11,920 6,280 5,640 8,870 4,810 4,060 
   Chronic myeloid leukemia 4,600 2,700 1,900 1,570 940 630 
   Other leukemia 4,900 2,880 2,020 6,610 3,690 2,920 
Other & unspecified primary sites‡ 31,090 15,930 15,160 45,170 22,10 23,160 
 
 
* Rounded to the nearest 10; excludes basal and squamous cell skin cancers and in situ 
carcinomas except urinary bladder. Carcinoma in situ of breast accounts for about 59,390 
new cases annually, and in situ melanoma accounts for about 40,780 new cases annually.  
 
† Estimated deaths for colon and rectum cancers are combined. 
 
‡ More deaths than cases suggests lack of specificity in recording underlying causes of death 
on death certificates.  
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As a result of the fact that cancer progresses in a time-dependent manner including 
several rate-limiting steps, many types of cancers show an increase of incidence in an 
age-dependent manner. Most cancer cases affect adults beginning in middle age and 
about 76% of all cancers are diagnosed at age 55 and older (American Cancer 
Society, 2004; Qin and Tang, 2002; Vogelstein and Kinzler, 2002; Weber, 2002; 
DeVita et al., 2001; Röcken and Carl-McGrath, 2001; Hanahan and Weinberg 2000; 
Hunter, 1997; Kinzler and Vogelstein, 1996). 
 
 
1.4. Cancer Genetics 
 
1.4.1. Tumor Suppressor Genes 
 
There is a big group of genes whose inactivation directly contributes to neoplasmic 
growth including TP53, RB1, VHL, WT, PTEN, NF-1, NF-2 and APC (Table 1.2). 
They function in growth control of cells and are said to be “gatekeepers” to prevent 
uncontrolled cell growth and named as tumor suppressors. Tumor suppressor genes 
are targets of loss-of-function mutations in cancer cells. They function in a diverse 
set of signaling and growth regulatory networks including cell cycle control, 
differentiation, cell-cell adhesion, apoptosis and maintenance of genomic integrity. 
As an example, in patients suffering from familial adenomatous polyposis (FAP), an 
inherited defect in the APC tumor suppressor gene results in development of 
hundreds of adenomatous polyps. The great number of those polyps guarantees the 
progression of some of them to malignant neoplasm.  
 
There is also an ever-increasing number of susceptibility genes including XPB, ATM, 
MSH2, and MLH1 that indirectly suppress neoplasia. Those genes are said to be 
“caretakers” of the genome and admitted to be a subset of tumor suppressor genes. 
They locate in DNA repair pathways, not in cell growth regulation or differentiation. 
While inactivation of a gatekeeper directly contributes to oncogenesis, inactivation of 
a caretaker contributes to increased mutation rate in the genome. For example, 
hereditary nonpolyposis colorectal cancer (HNPCC) leads to formation of 
adenomatous polyps in an individual at about the same rate as the general population 
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but since those patients are more open to have mutations because of defective 
mismatch repair, those polyps progress to cancer much more often when compared to 
general population (Vogelstein and Kinzler, 2002; Kinzler and Vogelstein, 1998; 
Kinzler and Vogelstein, 1996). 
 
The retinoblastoma gene (RB1) is the first tumor suppressor to be cloned and it is 
found to be mutated in retinoblastoma, small cell lung carcinoma (SCLC) and 
osteosarcoma. pRb has a role in cell cycle control, DNA replication, differentiation 
and apoptosis, interacting with more than 100 different cellular proteins. In pRb 
deficient cells, proliferation rate increases whereas differentiation decreases 
contributing to malignant phenotype (Classon and Harlow, 2002).  
 
TP53 is the most commonly mutated gene in human cancers with at least 50% of the 
tumors having abnormal TP53 gene. Moreover, there are some inactivating 
mutations of p53 function in some cancers. One of the examples is inactivation of 
p53 by HPV infection in cervical carcinoma. The reason of importance of TP53 lies 
in its multiple involvements in cellular processes. p53 functions in cell cycle control, 
apoptosis and maintenance of genetic stability. Therefore, loss of p53 activity is 
extremely dangerous in relation to cancer (Alberts et al., 2002; DeVita et al., 2001). 
 
 
1.4.2. Oncogenes 
 
RAS, MYC, EGFR, HER2, BCL-2, CCND-1, β-catenin, RET, SMO, MDM2 are some 
of the oncogenes that are frequently mutated in human cancers (Table 1.3). 
Oncogenes are altered forms of proto-oncogenes that are normal cellular genes 
whose proteins are highly conserved in evolution. Proto-oncogenic proteins function 
in networks that regulate cell cycle, apoptosis, cell division and differentiation. As a 
result, their expression is carefully regulated in different cell types during different 
stages of cell cycle and embryonic development. In oncogenesis, some of the 
oncogenes rescue cells from apoptosis and senescence by blocking cell 
differentiation whereas some of them liberate cells from their growth factor 
requirements. The activation of proto-oncogenes most frequently occur by
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Table 1.2: Some tumor suppressor genes and tumor suppressor proteins (taken from Vogelstein and Kinzler, 2002) 
 
Gene 
Associated inherited cancer 
syndrome 
Cancers with somatic mutations Presumed function of protein 
RB1 Familial retinoblastoma 
Retinoblastoma, osteosarcoma, SCLC, breast, 
prostate, bladder, pancreas, esophageal, others 
Transcriptional regulator; E2F binding 
TP53 Li-Fraumeni syndrome Approximately 50 % of all cancers Transcription factor; regulates cell cycle and apoptosis 
P16/INK4A 
Familial melanoma, familial 
pancreatic carcinoma 
25-30% of many different cancer types (e.g., 
breast, lung, pancreatic, bladder) 
Cyclin-dependent kinase inhibitor (i.e., cdk4 and cdk6) 
P14Arf(p19Arf) Familial melanoma? 15% of many different cancer types 
Regulates Mdm-2 protein stability and hence p53 stability; 
alternative reading frame of p16/INK4A gene 
APC 
FAP, Gardner syndrome, Turcot 
syndrome 
Colorectal, desmoid tumors 
Regulates levels of β-catenin protein in the cytosol; binding to 
microtubules 
WT-1 WAGR, Denys-Drash syndrome Wilms tumor Transcription factor 
NF-1 Neurofibromatosis type 1 Melanoma, neuroblastoma p21ras-GTPase 
NF-2 Neurofibromatosis type 2 Schwannoma, meningioma, ependymoma Juxtamembrane link to cytoskeleton 
VHL Von Hippel-Lindau syndrome Renal (clear cell type), hemangioblastoma Regulator of protein stability (e.g., HIFα) 
BRCA1 Inherited breast and ovarian cancer 10% of ovarian, rare in breast 
DNA repair; complexes with Rad 51 and BRCA2; transcriptional 
regulation 
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BRCA2 
Inherited breast (both female and 
male), pancreatic cancer, others? 
Rare mutations in pancreatic, others? DNA repair; complexes with Rad 51 and BRCA1 
MEN-1 Multiple endocrine neoplasia type 1
Parathyroid adenoma, pituitary adenoma, 
endocrine tumors of the pancreas 
Not known 
PTCH 
Gorlin syndrome, hereditary basal 
cell carcinoma syndrome 
Basal cell skin, medulloblastoma 
Transmembrane receptor for sonic hedgehog factor; negative 
regulator of smoothened protein 
PTEN/MMAC1 
Cowden syndrome, sporadic cases 
of juvenile polyposis syndrome 
Glioma, breast, prostate, follicular thyroid, 
head and neck squamous 
Phosphoinositide 3-phosphatase; protein tyrosine phosphatase 
DPC4 
Familial juvenile polyposis 
syndrome 
50% of pancreatic, 10-15% of colorectal, rare 
in others 
Transcriptional factor in TGF-β signaling pathway 
E-CAD Familial diffuse-type gastric cancer 
Gastric (diffuse type), lobular breast, rare in 
other types (e.g., ovarian) 
Cell-cell adhesion molecule 
LKB1/STK1 Peutz-Jeghers syndrome Rare in colorectal, not known in others Serine/threonine protein kinase 
EXT1 Hereditary multiple exostoses Not known Glycosyltransferase; heparan sulfate chain elongation 
EXT2 Hereditary multiple exostoses Not known Glycosyltransferase; heparan sulfate chain elongation 
TSC1 Tuberous sclerosis Not known Not known; cytoplasmic vesicle localization 
TSC2 Tuberous sclerosis Not known 
Putative GTPase-activating protein for Rap1 and rab5; golgi 
localization 
MSH2, MLH1, 
PMS1, PMS2, 
MSH6 
Hereditary nonpolyposis colorectal 
cancer 
Colorectal, gastric, endometrial DNA mismatch repair 
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Table 1.3: Oncogenes (taken from Vogelstein and Kinzler, 2002) 
 
Oncogene Neoplasm Proto-oncogene 
Growth factors 
v-sis Glioma/fibrosarcoma B-chain PDGF 
int 2 Mammary carcinoma Member of FGF family 
KS3 Kaposi sarcoma Member of FGF family 
HST Stomach carcinoma Member of FGF family 
int-I Mammary carcinoma Possible growth factor 
Receptors lacking protein kinase activity 
mas Mammary carcinoma Angiotensin receptor 
Tyrosine kinases: integral membrane proteins, growth factor receptors 
EGFR Squamous cell carcinoma Protein kinase (tyr) EGFR 
v-fms Sarcoma  Protein kinase (tyr) CSF-1R 
v-kit Sarcoma 
Protein kinase (tyr) stem cell 
factor R 
v-ros Sarcoma Protein kinase (tyr)  
MET MNNG-treated human osteocarcinoma cell line Protein kinase (tyr) HGF/SFR 
TRK Colon carcinoma Protein kinase (tyr) NGFR 
NEU(HER2) Breast carcinoma , neuroblastoma Protein kinase (tyr) 
RET Thyroid carcinoma Protein kinase (tyr) GDNFR 
Tyrosine kinases: membrane associated 
SRC Colon carcinoma Protein kinase (tyr)  
v-yes Sarcoma Protein kinase (tyr)  
v-fgr Sarcoma Protein kinase (tyr)  
v-fps Sarcoma Protein kinase (tyr)  
v-fes Sarcoma Protein kinase (tyr)  
BCR/ABL Chronic myelogenous leukemia Protein kinase (tyr)  
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Membrane-associated G proteins 
H-RAS Colon, lung, pancreas carcinoma GTPase 
K-RAS 
Acute myelogenous leukemia, thyroid carcinoma, 
melanoma 
GTPase 
N-RAS 
Neuroblastoma, acute myeloid leukemia, multiple 
myeloma, melanoma 
GTPase 
gsp Thyroid carcinoma G6α 
gip Ovary, adrenal carcinoma G1α 
GEF family of proteins 
Dbl Diffuse B-cell lymphoma GEF for Rho and Cdc42Hs 
Ost Osteosarcomas GEF for RhoA and Cdc42Hs 
Tiam-1 T lymphoma GEF for Rac and Cdc42Hs 
Vay Hematopoietic cells GEF for Ras? 
Lbc Myeloid leukemias GEF for Rho 
Serine/threonine kinases: cytoplasmic 
v-mos Sarcoma Protein kinase (ser/thr) 
v-raf Sarcoma  Protein kinase (ser/thr) 
pim-1 T-cell lymphoma Protein kinase (ser/thr) 
Nuclear protein family 
N-MYC Neuroblastoma, lung carcinoma Transcription factor 
L-MYC Lung carcinoma Transcription factor 
v-myb Myeloblastosis  Transcription factor 
v-fos Osteosarcoma Transcription factor API 
v-jun Sarcoma Transcription factor API 
v-ski Carcinoma Transcription factor 
v-rel Lymphatic leukemia Mutant NFκB 
v-ets Myeloblastosis Transcription factor 
v-erbA Erythroblastosis  Mutant thioredoxine receptor 
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amplification of those genes, by point mutations, by proviral insertion and gene 
rearrangements. 
 
The complex network of growth inhibitory and growth stimulatory pathways 
necessitates the interconnection of tumor suppressors and oncogenes on the same 
pathway for a regular control of cell growth. This fact underlines the importance of 
such interconnected pathways. Therefore, the acquisition of sequential alterations 
involving both oncogenes and tumor suppressor genes is required for the progression 
of the malignant phenotype (Vogelstein and Kinzler, 2002; Hunter, 1997). 
 
 
1.5. Selected Cancer Types 
 
1.5.1. Bone Cancer (Sarcomas of the Bone)  
 
The most common bone tumor is osteosarcoma and it generally occurs in childhood 
and adolescence. Osteosarcoma is a high-grade, malignant spindle cell tumor with 
poor prognosis accounting for 5% of the tumors in childhood. Bones of the knee joint 
are the most common sites for this cancer. Generally, 80-90% of osteosarcomas arise 
in the long tubular bones. The most important prognostic feature of the tumor is its 
resectability because this tumor is highly resistant to radiotherapy. Osteosarcoma is 
found to be not associated with a specifically recurrent translocation or any other 
specific chromosomal rearrangements. However, inactivation of RB1, TP53, INK2A, 
INK4A genes, deregulation of CDK4, and over-expression of MDM2, MYC, HER2 
and CCND1 genes are reported (Sandberg and Bridge, 2003; DeVita et al., 2001; 
http://www.cancer.gov/cancertopics/pdq/treatment/osteosarcoma/healthprofessional). 
 
 
1.5.2. Breast Cancer:  
 
Breast cancer is the most frequent non-skin cancer type among women. It ranks 
second among cancer deaths in females. Increased risk-associated factors for the 
disease are a personal or family history of breast cancer (e.g., carrying mutated 
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BRCA1 and BRCA2 genes, which are high-penetrance breast cancer susceptibility 
genes), atypical hyperplasia in the breast, a long menstrual history, obesity, 
postmenopausal hormone therapy of combination of estrogen and progestin, never 
having children, and excessive consumption of alcoholic beverages.  
 
Most of the breast cancers are ductal type. Hereditary breast cancer accounts for 5 to 
15% of all breast cancer cases. Breast cancer patients who carry an altered gene 
related to the disease have an increased risk of developing ovarian cancer. Somatic 
alterations in breast cancer include the genes that are displayed in Table 1.4 
(American Cancer Society, 2004; Vogelstein and Kinzler, 2002, DeVita et al., 2001; 
http://www.cancer.gov/cancertopics/pdq/treatment/breast/patient). 
 
Table 1.4: Somatic alterations in breast cancer (taken from Vogelstein and Kinzler, 
2002) 
 
 
 
Gene/Region Modification Frequency 
Growth factors and receptors 
EGFR Overexpression 20-40% 
HER-2/neu Overexpression 20-40% 
FGF1/FGF4 Overexpression 20-30% 
TGFα Overexpression Not reported 
Intracellular signaling molecules 
Ha-ras Mutation 5-10% 
c-src Overexpression 50-70% 
Regulators of cell cycle 
TP53 Mutation/inactivation 30-40% 
RB1 Inactivation 20% 
Cyclin D Overexpression 35-45% 
TGF-β Deregulation  Not reported 
Adhesion molecules and proteases 
E-cadherin Reduced/absent 60-70% 
P-cadherin Reduced/absent 30% 
Cathepsin D Overexpression 20-24% 
MMPs Increased expression 20-80% 
Other genes 
bcl-2 Overexpression 30-45% 
c-myc Amplification 5-20% 
nm23 (NME1) Decreased expression Not reported 
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1.5.3. Cervical Cancer  
 
Cancer of uterine cervix risk is closely related to the sexual behavior of the 
individual. Sexually transmitted infections caused by several strains of human 
papilloma virus (HPV), sexual activity starting at an early age, having many sexual 
partners or having sexual partners who have had many sexual partners increase the 
risk of cervical cancer. Besides, cigarette smokers and overweight patients are at 
disadvantage in the disease progression. For women aged between 20 and 39 years, 
cervical cancer is the second leading cause of cancer-related deaths ranking after 
breast cancer in U.S. However, Pap test is a routine diagnostic tool that can be 
simply used as a part of pelvic examination for detection of abnormal cells and 
fortunately, most cervical precancers grow slowly.  
 
In the disease progression with HPV infection, HPV E6 and E7 oncoproteins interact 
directly with p53 and pRB tumor suppressor proteins, respectively. This leads to 
degradation of p53 protein by ubiquitin pathway and inactivation pRB protein. c-myc 
and HER2 gene amplifications are also reported in cervical cancer cases (American 
Cancer society, 2004; Vogelstein and Kinzler, 2002; DeVita et al., 2001). 
 
 
1.5.4. Colon and Rectum Cancers 
 
In U.S., colon and rectum cancers account for the third most commonly diagnosed 
cancer both in males and females. In addition, it ranks third among mortality rates for 
both sexes. This ranking accounts for 10% of deaths caused by cancer. The disease is 
highly age-dependent with more than 90% of cases diagnosed in individuals older 
than age of 50. Half of the Western population develops benign colorectal tumors 
(adenomatous polyps) by age 70, and a fraction of those sporadic tumors progress 
into cancer (American Cancer society, 2004; Vogelstein and Kinzler, 2002; Kinzler 
and Vogelstein, 1998). 
 
As mentioned before, tumorigenesis is a process involving activation of oncogenes 
and inactivation of tumor suppressor genes. In colorectal cancer, the presence of 
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aberrant crypt foci (ACF) is the earliest premalignant lesion. Dysplastic form of ACF 
is referred to as adenomatous crypts (microadenoma) and the most frequent reason of 
this form is loss of heterozygosity on 5q of the adenomatous polyposis coli (APC) 
gene. Dysplastic ACF are precursors of the adenomatous polyps, which further 
become colon carcinoma lesions. TP53 gene mutations appear to be of significant 
importance during transition from adenoma to high-grade dysplasia. When 
compared, TP53 mutation is a late event in contrast to APC gene mutation that is the 
earliest genetic event in colorectal cancer progression (Luebeck and Moolgavkar, 
2002). Among the several inherited predispositions to colorectal cancer, the two best 
characterized are HNPCC and FAP. Notwithstanding, those two account for a small 
fraction of all cases and most cases still retain a sporadic character. K-RAS, H-RAS, 
N-RAS, CTNNB1 oncogene mutations are frequently observed in colorectal tumors. 
The most frequently mutated tumor suppressor genes other than APC and TP53 are 
DCC, SMAD4/DPC4, SMAD, TGFBRII, hMSH2, hMSH3, hMSH6, hMLH1 hPMS1, 
and hMLH1 (Vogelstein and Kinzler, 2002; Grady and Markowitz, 2002; Buda and 
Pignatelli, 2002;  Röcken and Carl-McGrath, 2001; Kinzler and Vogelstein, 1996; 
http://www.cancer.gov/cancertopics/pdq/treatment/colon/). 
 
 
1.5.5. Kidney Cancer 
 
Renal cell cancer, also called renal adenocarcinoma or hypernephroma, is a 
malignant neoplasm found in the lining epithelium of tubules in the kidney. Similar 
to many other cancer types, renal cell cancer can often be cured if it is diagnosed and 
treated at a localized stage to the kidney and to the very nearby surrounding tissue. 
96% of the renal carcinoma cases are sporadic and there is a strong correlation 
between cigarette smoking, exposure to asbestos and development of renal 
carcinoma. VHL tumor suppressor gene mutations are of significant importance in 
renal cell tumorigenesis (DeVita et al., 2001; http://www.cancer.gov/cancertopics/ 
pdq/treatment/renalcell/healthprofessional; http://www.cancer.gov/cancertopics/pdq/ 
treatment/renalcell/patient). 
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1.5.6. Liver Cancer 
 
Among all primary liver malignancies, hepatocellular carcinoma (HCC), which is 
carcinoma of hepatocytes, accounts for 90% of all cases and most of these cases arise 
from chronic liver infection by Hepatitis B and Hepatitis C viruses, accompanied by 
underlying cirrhosis. Hepatocyte necrosis, inflammation, regeneration, and fibrosis 
are associated with hepatitis and it may proceed to cirrhosis. Quiescent cells start to 
proliferate following liver necrosis, and chronic hepatitis consists of repetitive cycles 
of necrosis and regeneration that facilitate cancer development. The pathways that 
are suggested to be important in HCC development are p53, pRB, TGF-β and 
APC/β-catenin pathways. In addition, c-myc, c-fos, H-ras, N-ras and insulin-like 
growth factor gene are suggested to involve in oncogenic activation. Furthermore, 
there are environmental, metabolic (e.g., hemochromatosis, glycogen storage disease 
type 1), nutritional (e.g., aflatoxin B1 uptake, excessive alcohol consumption) and 
endocrine factors that may contribute to hepatocarcinogenesis.  
 
HCC is a highly malignant disease with poor prognosis and most cases are lately 
diagnosed. It ranks fifth in frequency in the world and has a male preponderance 
(2:1; male: female). HCCs are almost always soft tumors with the exception of the 
fibrolamellar variant (FLC), which is rare. All the same, FLC differs from other 
HCCs in female preponderance, young mean age of the patients (23 years) and its 
usual occurrence in the absence of cirrhosis. Serum alpha-fetoprotein is usually 
normal in FLC contrary to patients with underlying cirrhotic disease who display a 
progressive increase in alpha-fetoprotein (AFP) and/or in alkaline phosphatase. 
FLC’s importance results from the fact that an increased proportion of fibrolamellar 
carcinoma patients may be cured if the tumor can be resected.  It also generally 
exhibits a slower clinical course than the more common hepatocellular carcinoma.  
 
Hepatoblastoma is another malignant tumor of liver and it has embryonic origin with 
differing patterns of differentiation. Hepatoblastoma usually does not spread outside 
the liver (Nita et al., 2002; Röcken and Carl-McGrath, 2001; Dürr and Caselmann, 
2000; Habib, 2000; Robinson, 1994; http://www.cancer.gov/cancerinfo/pdq/   
treatment/adultprimaryliver/HealthProfessional; http://www.cancer.gov/cancertopics/ 
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pdq/treatment/adult-primary-liver/patient; http://www.vh.org/adult/provider/ 
pathology/LiverPathology/Text/11Epithelial.html). 
 
 
1.5.7. Myeloma 
Myeloma is the systemic neoplasm of B cells, and the most common type is multiple 
myeloma. In multiple myeloma, cancerous plasma cells are found in the bone 
marrow. The small tumors made by plasma cells that collect in the bone are called 
plasmacytomas.  
Macroglobulinemia is a type of plasma cell neoplasm in which lymphocytes that 
make an M-protein build up in the blood. Lymph nodes, liver and spleen may be 
swollen.  
Despite the fact that it is rarely curable, myeloma is a highly treatable disease. Since 
the cancer arises from a single cell by clonal expansion, too many amount of 
monoclonal antibody and monoclonal (or myeloma) protein (M-protein) is found in 
the serum and/or urine of the myeloma patients at the time of diagnosis. Exposure to 
ionizing radiation is the major environmental cause of myeloma. Other potential 
environmental risk factors include exposure to nickel, agricultural chemicals, 
benzene, petroleum products and silicon. More than 40% of all myeloma cases have 
deletion in RB1 gene. Additionally, scientists report constitutive phosphorylation of 
pRB. The high frequency of abnormalities in p16 (75%) and p15 (67%) suggests the 
importance of pRB regulatory pathway in myeloma development. Furthermore, the 
most common translocation involving 14q32 results in overexpression of cyclin D 
(DeVita et al., 2001; http://www.cancer.gov/cancertopics/pdq/treatment/myeloma/ 
healthprofessional; http://www.cancer.gov/cancertopics/pdq/treatment/myeloma/ 
patient). 
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1.5.8. Malignant Melanoma 
 
Melanocytes are the pigment producing cells of the skin from which malignant 
melanoma arises. Melanoma is the most serious type of all skin cancers. Since it is 
10 times more common in whites than in African Americans, it is admitted to be a 
disease of whites. Melanoma has a quickly spreading character but is highly curable 
when detected in its early, localized stages. Exposure to UV irradiation is the most 
influencing environmental factor of the disease. There are some loss of 
heterozygosity (LOH) regions that are frequently coupled to melanoma formation. 
Three of those regions contain metastasis suppressor gene NM23 and tumor 
suppressor genes NF1 and PTEN. MLM, p16, p15, p19ARF and CDK4 are the genes 
whose mutations influence melanoma (American Cancer Society, 2004; Vogelstein 
and Kinzler, 2002; DeVita et al., 2001). 
 
 
1.5.9. Prostate Cancer 
 
Prostate cancer has the highest incidence among other cancers in men and 
unfortunately, it is the second leading cause of cancer deaths following lung cancer. 
Similar to colon and rectum cancers, more than 70% of the individuals diagnosed 
with this disease are over the age of 65. Histologically, more than 95% of the 
prostate tumors are adenocarcinomas that arise from acinar cells of the prostate.  The 
genes that are found to be mutated in prostate cancer include p53, PTEN, RB1, RAS, 
p16, Bcl-2, E-cadherin and androgen receptor (American Cancer Society, 2004; 
Vogelstein and Kinzler, 2002; DeVita et al., 2001). 
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1.6. Hybridoma Technology and Monoclonal Antibody Production 
 
B lymphocytes generate humoral immune response that is polyclonal and therefore, 
the antibodies present in an individual are heterogeneous. However, one can obtain 
large amounts of homogeneous antibody reacting with a single epitope (monoclonal) 
by cloning B lymphocytes. From the time that Koehler and Milstein introduced 
hybridoma technology based on this fact, scientists have identified a broad range of 
biological molecules with the help of monoclonal antibodies. Immune stimulatory 
and regulatory molecules, cellular markers for distinguishing the tissue origin of one 
cell from another, cellular and tumor markers for characterization of the nature of a 
tumor biopsy specimen, the antigens that are up- or down-regulated in tumor cells 
are some of the biomolecules in this range. Additionally, monoclonal antibodies are 
used in therapeutic approaches to target cytotoxic reagents to and trigger or block 
cell surface molecules, and in diagnostic approaches to carry imaging reagents to 
tumors (Table 1.5) (White et al., 2001; DeVita et al., 2001; Goding 1983).  
 
Antibody-secreting hybridoma is the fusion of an indefinitely growing myeloma cell 
and an immune B lymphoblast expressing a specific antibody gene. Myeloma cells 
are established to be deficient for hypoxanthine guanine phosphoribosyl transferase 
(HGPRT) enzyme. Polyethylene glycol, which is a polywax, is used to facilitate cell 
fusion because it promotes cell adherence and the exchange of nuclei. HAT medium 
that contains hypoxanthine, aminopterin and thymidine is used to select successfully 
fused cells because only hybrid cells can grow in this medium. Homogeneous cell 
clones that secrete only one specific antibody are obtained by limiting dilution 
(Abbas and Lichtman, 2003; Little et al., 2000).  
 
The culture of a hybridoma cell line can yield 1-10 µg of Ig per ml supernatant. 
Ascites fluids can produce between 1 and 10 mg of Ig per 1 ml (DeVita et al., 2001). 
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Table 1.5: Clinical applications of monoclonal antibodies (mAbs) in cancer (taken 
from DeVita et al., 2001) 
 
Diagnosis  
Screening of body fluids for the presence of circulating TAA* 
Nuclear scanning with radiolabeled mAb 
Detection of primary or metastatic lesions (intravenous, subcutaneous, or iliopsoas administration of 
radiolabeled mAb) 
The use of radiolabeled mAb and intraoperative γ detecting probe 
Immunopathology  
Diagnosis of malignant versus benign 
Differential diagnosis of tumor type 
Subclassification of tumor based on TAA expression 
Metastatic potential 
Specific favored sites of metastasis 
Predicted response (or lack of thereof) to specific therapeutic regimens 
Prognosis  
Monitoring of disease progression 
Screening of body fluids for circulating TAA 
Nuclear scanning with radiolabeled mAb to detect or quantify tumor recurrence  
Immunopathology for detection of occult metastases  
Aspiration cytology 
Lymph node or bone marrow biopsy 
Cytology of body fluids 
Therapy  
Direct cytotoxicity of mAb 
Complement mediated 
Cell mediated 
Drug conjugation of mAb (e.g., doxorubicin) 
Toxin conjugation of mAb (e.g., ricin) 
Radionuclide conjugation of mAb (e.g., α or β emitters) 
Ex vivo tumor removal from harvested bone marrow 
Inhibition of receptors for growth factors 
Administration of antiidiotype mAbs to induce specific active immunity to tumor antigens  
 
 * Tumor-associated antigen 
 - 20 -
1.7. Tumor Markers  
 
Tumor markers are products that are often detected in higher-than-normal amounts in 
the blood or other body fluids or tissues of some individuals with certain types of 
cancer. Tumor markers are produced either by the tumor itself (e.g., tumor antigens) 
or by the body in response to the presence of cancer. Tumor markers can be 
classified into three categories in terms of the aim of use:  
 
1. Diagnostic Markers: They give clues for identifying a disease by its signs, 
symptoms and laboratory findings.  
2. Prognostic Markers: They help to predict the course of the disease. 
3. Therapeutic Markers: They pertain with the treatment of the disease. They 
are typically of IgG class molecules. 
 
There are cell surface markers (e.g., phenotypic CD antigens of hematopoietic cells), 
genetic markers (e.g., Philadelphia chromosome), secreted proteins (e.g., 
paraproteins in the serum), oncofetal proteins (e.g., carcinoembryonic antigen, α-
fetoprotein), hormones (e.g. human chorionic gonadotropin), enzymes (e.g., prostate-
specific antigen, lactic dehydrogenase, neuron-specific enolase) and cancer antigens 
(e.g., CA 125, CA 15-3, CA 19-9) whose elevated levels or abnormal expression 
pattern is used for diagnostic, prognostic or therapeutic purposes (Table 1.6). 
Anyone may notice that a tumor marker can have more than one of the features 
mentioned in the sentence before (e.g., carcinoembryonic antigen is a cell surface 
protein and an oncofetal protein) (http://lwwoncology.com; http://cis.nci.nih.gov/ 
fact/5_18.htm). This thesis will focus on protein markers because of the design of the 
thesis project.  
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Table 1.6: Some serum and immunohistochemical markers (taken and adapted from 
http://lwwoncology.com) 
 
Marker Associated Cancer Type 
α-Fetoprotein Testis, hepatocellular, upper gastrointestinal, germ cell, 
trophoblastic tumors 
α-Lactalbumin  Breast 
β2-microglobulin Myeloma, lymphoma 
CA 15–3  Breast 
CA 19–9 Pancreas, transitional cell tumors 
CA 125 Ovary, cervix, endometrium, gastrointestinal tract, breast 
Calcitonin  Thyroid (medullary carcinoma) 
CD antigens  Lymphoma, leukemia, myeloma, endothelial cells 
Carcinoembryonic antigen  Colorectal, breast, lung (small cell), gut, pancreas, cervix, urinary 
tract, medullary thyroid  
β1-Antitrypsin Hepatocellular  
Chromogranin  Neuroendocrine  
Collagen type IV Sarcoma (neurogenic, smooth muscle) 
Cytokeratins  Carcinomas, rarely sarcomas 
Desmin Sarcoma (muscle) 
Factor VIII Vascular sarcomas 
Glial fibrillary acidic protein Glial cell tumors, astrocytomas, oligodendrogliomas, 
ependymomas, schwannomas 
Gross cystic disease fluid protein Breast  
HER1 Lung  
HER2 Breast, ovary, bladder, pancreas, colon, lung 
Human chorionic gonadotropin Testis, trophoblastic neoplasia, breast 
Human placental lactogen  Trophoblastic tumors, germ cell tumors, gastric, lung 
Immunoglobulin molecules Lymphoma, leukemia 
Involucrin  Squamous epithelia 
Ki-67  All tumor types 
Leukocyte common antigen Lymphoma, leukemia, histiocytic tumors 
Muramidase  Histiocytic tumors, myelogenous leukemia  
Myelin basic protein  Neurogenic sarcoma 
Myoglobin  Sarcoma, corpus uteri 
Muscle-specific actin  Sarcoma 
Neurofilaments  Neuroendocrine; small cell lung 
Neuron-specific enolase  Neuroendocrine; small cell lung, breast 
NKI/C3  Melanoma 
Pancreatic carcinoma antigen  Pancreas, gut 
Prostate-specific antigen  Prostate 
Prostate-specific membrane antigen  Prostate 
S100 protein Melanoma, sarcoma, histiocytic tumors, glioma 
Vimentin  Sarcoma, renal cell carcinoma, melanoma, lymphoma, leukemia 
Thyroglobulin Thyroid 
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1.8. Selected Tumor Markers 
 
1.8.1. CA 125 
 
CA 125 is an antigenic determinant on a high molecular weight glycoprotein and one 
of its two antigenic domains is recognized by the murine monoclonal antibody OC-
125 and the other is recognized by the monoclonal antibody M11. Inclusion cysts, 
metaplasic parts and papillary excrescences found in ovary express CA 125 
determinant but it is not expressed in the normal surface epithelium of fetal or adult 
ovaries. CA 125 is elevated in 85% of epithelial ovarian cancers and 13-21% of 
squamous carcinoma. In ovarian cancer, preoperative serum level of CA 125 is found 
to be correlated with tumor stage and histological grade but it is not suggested to be 
an independent prognostic or diagnostic factor on its own. Elevation of serum CA 
125 can also be associated with pancreas, breast, colon, lung malignant neoplasms as 
well as with some benign neoplasms and physiological states such as pregnancy, and 
menstruation (Robertson et al., 2002;  Meyer and Rustin, 2000; 
http://lwwoncology.com). The major contribution of CA 125 as a tumor marker is 
said to be its utility in the monitoring of tumor response to chemotherapy (Verheijen 
et al., 1999). 
 
 
1.8.2. Carcinoembryonic Antigen (CEA) 
 
CEA is an oncofetal serum antigen and it is present in small amounts in adult colon. 
If an increased serum level of CEA is detected in a pretreatment stage, it implies a 
negative prognostic significance for the patient. Serum level elevation of CEA is 
related to many cancer types including colon, rectum, gallbladder, pancreas and 
stomach. It is frequently used in the management of patients with rectal, colon, 
gallbladder and stomach cancers but it is suggested that CEA is not useful by itself 
for screening those cancers and use of CEA alone for monitoring response to 
treatment is not recommended. This is as a result of lack of tumor type specificity of 
CEA. Additionally, benign diseases of liver, gastrointestinal tract, lung and cigarette 
smoking may cause elevation of CEA levels decreasing its tumor specificity 
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(http://lwwoncology.com; http://www.cancer.gov/cancerinfo/pdq/treatment/rectal/ 
HealthProfessional). 
 
 
1.8.3. Alpha-Fetoprotein (AFP) 
 
AFP is an oncoprotein, too. This glycoprotein is produced by fetal yolk sac, liver, 
and upper gastrointestinal tract. Pregnancy and benign liver disease also cause the 
elevation of AFP. Serum levels of this protein are increased in most of liver tumors 
and in some of the gastric, pancreatic, colon, and bronchogenic cancers. AFP is 
accepted to be the best diagnostic serum tumor marker for primary liver cancer. It is 
suggested that AFP is a reliable factor for monitoring therapeutic response and 
detecting recurrences in women with endodermal sinus tumors and embryonic 
carcinomas (Uenishi et al., 2003; http://lwwoncology.com). 
 
 
1.8.4. CD20 
 
CD20 is a transmembrane protein present on almost all of the B cells from the time 
of their commitment to B cell development until the time that the protein is down-
regulated in the differentiated, antibody-secreting plasma cells. Therefore, CD20 is 
accepted as a pan-B cell antigenic marker. The expression of CD20 is quite 
heterogeneous both in the tumor sample of an individual and among different 
lymphoma types.  
 
The first monoclonal antibody to be approved by U.S. Food and Drug Administration 
(FDA) for the therapy of cancer is rituximab (Rituxan®, 1997). Rituximab is used to 
target CD20 that is present in many B cells of non-Hodgkin’s lymphoma subtypes. It 
induces apoptosis, antibody-dependent cell cytotoxicity and complement mediated 
cytotoxicity in these tumors. When used in combination with other 
chemotherapeutics, it significantly improves disease-free survival rates (Smith, 2003; 
Ross et al., 2003; White et al., 2001; Glennie et al., 2000; Maloney et al., 1994). 
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1.8.5. Cytokeratins 
 
Cytokeratins are intermediate filaments that build cytoskeleton, being a member of it 
in all epithelial cells. They are specific markers of epithelial differentiation and 
although not the same, they are continued to be expressed after malignant 
transformation. More than 20 cytokeratins have been described in humans. One of 
the applications of those proteins is their use in differential diagnosis of epithelial 
tumors and detecting their differentiation status. Cytokeratin fragments can be 
detected in the serum by monoclonal antibodies because in malignant epithelial cells, 
activated proteases degrade cytokeratins into fragments that are soluble in the serum. 
CYFRA 21-1 is an assay developed to measure a soluble fragment of CK 19 in the 
serum. In non-small cell lung cancer (NSCLC), CYFRA 21-1 is more sensitive than 
any other established markers. Moreover, it is found to be a useful marker for 
cervical, esophageal, breast, gastric, and bladder cancers. Uenishi et al. (2003) 
suggest CYFRA 21-1 as a useful diagnostic test for intrahepatic cholangiocarcinoma 
patients because CK 19 is differentially expressed in bile duct cells of normal liver 
whereas normal hepatocytes do not express it (Upasani et al., 2004; Uenishi et al., 
2003; Young et al., 2002;  Kamoi et al., 2002; http://lwwoncology.com). 
 
In a study of differential expression of cytokeratin 18 (CK 18) in NSCLC subtypes of 
adenocarcinoma, squamous cell carcinoma and adenosquamous carcinoma, it was 
found that CK 18 expression was strongest in adenocarcinoma, weak in 
adenosquamous carcinoma and undetectable in squamous cell carcinoma concluding 
that CK18 might be of diagnostic value for those subtypes (Young et al., 2002).  In 
another study involving anal carcinoma, the authors concluded that loss of 
expression of CK 18 and CK 19 is a marker of dedifferentiation in anal carcinoma 
(Behrendt and Hansman, 2001). Ordonez  (2002) underlines that CK 5/6 is among 
the most useful positive immunohistochemical markers for epitheloid mesothelioma 
diagnosis. 
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1.8.6. HER2 
 
HER2 (erbB2) belong to the erbB family of tyrosine kinase receptors (RTKs) -also 
known as type I receptor tyrosine kinases or EGF receptor family- and it is a relative 
of HER1. In normal cells, activation of erbB RTKs triggers a broad network of 
signaling pathways controlling cell growth, differentiation, motility and adhesion. 
Deregulation of HER2 receptor is observed in many cancers leading to a more 
aggressive clinical outcome of the disease. In breast cancer, nearly 25% to 30% of 
patients have overexpression of HER2 caused by amplification of HER2 gene. This 
amplification is associated with a poor prognosis and chemoresistance of tumor in 
breast cancer patients. In addition, HER2 has a metastasis-promoting effect 
promoting the secretion of matrix metalloproteases.  
 
The hypothesis that the blockage of binding of epidermal growth factor (EGF) to its 
receptor might prevent cell proliferation by inhibiting receptor activation influenced 
production of anti-EGF receptor monoclonal antibodies. HER2 is the target of the 
first monoclonal antibody approved by FDA as an erbB receptor inhibitor, 
trastuzumab (Herceptin®; Genentech, Inc.; South San Francisco, CA). The 
metastatic breast cancer patients with a profile of HER2 over-expression benefit from 
therapies involving trastuzumab. HER2-targeted therapies can lead to tumor 
regression, delay of tumor growth and some symptomatic improvements. There is a 
consensus among researchers on prognostic value of HER2 amplification/over-
expression in node-positive breast cancer patients. In addition, HER2 over-
expression has a negative predictive value for the responsiveness of the cancer 
patients to chemotherapy and endocrine therapy indicating the probability of 
resistance to those therapies.  Apart from this, the approval of trastuzumab provided 
the use of an immunohistochemical diagnostic test (HercepTest™). HercepTest™ is 
designed specifically to detect HER2 protein over-expression in routinely processed 
breast cancer tissues. HercepTest™ is approved by FDA for the measurement of 
HER2 status when deciding whether patients are eligible for Herceptin® therapy. In 
Europe, patients are accepted to be eligible for treatment if they demonstrate IHC 3+ 
HER2 over-expression and in the U.S. patients are eligible if they demonstrate 2+ or 
3+ HER2 over-expression. Therefore, HercepTest™ aims a reliable detection of 
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HER2 over-expression for the success of Herceptin® therapy. (Menard et al., 2003; 
Rowinsky 2003; Ross et al., 2003; White et al., 2001; Hanahan and Weinberg, 2000; 
Mendelsohn and Baselga, 2000; Glennie and Johnson, 2000; 
http://www.dakocytomation.com/dako_facts_1final.pdf). 
 
 
1.8.7. Prostate-Specific Antigen (PSA) 
 
The measurement of PSA levels in serum is utilized for screening and early detection 
of prostate cancer. However, PSA is not a highly specific tumor marker. Serum 
contains two forms of PSA; complexed PSA and free PSA. There are three forms of 
free PSA and the one that is a proenzyme is associated with cancer of prostate. The 
ratio of elevated serum level of truncated proenzyme PSA to total serum PSA 
correlates with an increased risk of prostate cancer (Mikolajczyk et al., 2002; Peter et 
al., 2001; Mikolajczyk et al., 2000).  
 
 
1.8.8. Prostate-Specific Membrane Antigen (PSMA) 
 
PSMA is a tissue-specific protein that is accepted to be a very good target for 
imaging and therapy because of its prostate specificity and its extracellular large 
domain. Although PSMA is expressed in kidney, proximal small intestine, salivary 
gland and brain, those tissues have a thousand-fold smaller expression levels than 
that of prostate. PSMA is up-regulated many folds in prostate cancer and 
interestingly, it is expressed in neovascularizations of most of the solid tumors but 
not in neovascularizations of normal tissues (Ghosh and Heston, 2004). 
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2. AIM OF THE STUDY 
 
Utilization of tumor markers in cancer research and in clinical applications provides 
benefit of differential diagnosis of cancer versus normal or benign tissue, differential 
diagnosis of tumor degree, tumor types and subtypes, predicting the prognosis of the 
disease, and targeted treatment of the tumor versus normal tissue, selectively. 
Although there are many tumor markers investigated on the basis of monoclonal 
antibody production, very few markers are specific in terms of cancer and tissue 
type. This feature restricts the use of tumor markers leading to lack of routinely used 
informative tumor markers in many cancer types. Therefore, investigation of novel, 
informative tumor markers is in great demand.  
 
This study aims production of monoclonal antibodies that may be candidates for 
fulfilling the requirements of an ideal tumor marker. To serve this purpose, two 
monoclonal antibodies were produced against apoptosis induced hepatocellular 
carcinoma cell line HuH-7. Next, the monoclonal antibodies were subjected to 
characterization experiments to explore their immunoreactivity in different cell, 
tissue and tumor types. 
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3. MATERIALS AND METHODS 
 
3.1. Production of 6D5 and 9C11 Monoclonal Antibodies 
 
3.1.1. Production of 6D5 and 9C11 Monoclonal Antibody Producing  
          Hybridomas 
 
6D5 and 9C11 producing hybridomas were previously produced by Tamer Yagci. 
Ten million of cells of apoptosis induced (by UV-C irradiation, 60-120 mJ/cm²) 
HuH-7 hepatocellular carcinoma cell line was lysed in 2 ml PBS and 0.5 ml of lysate 
was injected into peritoneal cavity of Balb/c mice. Mice were immunized twice more 
at two weeks intervals and hybridomas were prepared by spleen cells after the 
animals were sacrificed. Sp2/0-Ag14 mouse myeloma cell line was used as fusion 
partner.  
 
Partaking in the project at the time of culturing after the fusion, the antibody 
producing hybridoma cells were selected by enzyme-linked immunosorbent assay 
(ELISA). HuH-7 cells were grown in 96-well tissue culture plates in DMEM medium 
(supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM 
L-glutamine and 0.1 mM non-essential amino acids) in tissue culture incubator that 
was set to 37 ºC and 5% CO2. When they reached to desired number, they were fixed 
with 4% formalin in PBS for 15 minutes in dark at room temperature. Afterwards, 
they were permeabilized with 0.2% Triton X-100 in 1X PBS for 5 minutes at room 
temperature. Then, the plates were washed two times with distilled water and dried 
gently by tapping on a paper towel. 2% BSA in PBS was used for blocking and the 
cells were incubated with this blocking solution for 1 hour at 37 ºC. Blocking was 
followed by addition of hybridoma supernatants to the wells that contain HuH-7 
cells. The cells were incubated with the supernatants for 1 hour at 37 ºC. Following 
incubation, wells were washed 2 times with distilled water and secondary antibody 
(goat anti-mouse IgG-alkaline phosphatase, Sigma) was added as 1:1000 diluted. 
After an incubation period of 1 hour at 37 ºC, the wells were washed 4 times with 
distilled water. Next, substrate tablet (pNPP disodium hexahydrate, phosphatase 
 - 29 -
substrate, Sigma) was dissolved in 20 ml ddH2O in dark at room temperature and 
added to each well. At the end of 20-45 minutes of incubation, spectrophotometric 
measurement was performed at A405 at Beckman Biomek ELISA reader. DMEM 
containing wells were used as negative control. The supernatants were accepted to 
produce antibody if they had an optic density twice of that of the negative control. 
 
After ELISA assay, the positive hybridoma cells were cloned by limiting dilution. 
The hybridoma cells were counted and they were plated to 96-well plates with a 
calculated theoretical amount of 0.5 cell per well. Recloning was done to ensure 
clonality of the cells. 
 
Clones, producing different antibodies of single cell origin, were screened again by 
the same ELISA method described before. The antibody producing clones to be 
selected for further studies were determined from the ones that revealed a 
measurement result of three times that of the negative control.  
 
Two of the antibody producing clones, namely 6D5 and 9C11, were chosen to be 
used for further studies.  
 
 
3.1.2. Culturing 6D5 and 9C11 Hybridoma Cells for Antibody Production 
 
6D5 and 9C11 hybridoma cells were cultured in high glucose containing DMEM 
medium supplemented with 20% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 
and 0.1 mM non-essential amino acids. The incubator where the cells were grown 
was set to 37 ºC and 5% CO2. The hybridoma supernatants were collected by 
centrifugation of the cultures at 1500 rpm for 5 minutes at room temperature. They 
were buffered with 20 mM Tris (pH 8) and 0.02% sodium azide (w/v) was added as 
preservative to prevent microorganism contamination. The supernatants were stored 
at -20 ºC if they were not going to be used immediately. New stocks were prepared 
by freezing 10 million hybridoma cells in 90% FCS and 10% DMSO containing 
freezing medium. 
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3.2. Western Blotting With 6D5 and 9C11 Monoclonal Antibodies 
 
3.2.1. Tissue Culture Studies 
 
28 cell lines (Table 3.1) were grown as monolayer culture in 150 mm culture dishes 
in tissue culture facility incubator that was set to 37 ºC and 5% CO2. The culture 
media were supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 2 mM L-glutamine and 0.1 mM non-essential amino acids.  
 
 
Table 3.1: The cell lines used in Western blotting with 6D5 and 9C11 antibodies 
 
Cell line Organism Tissue/Cancer type Medium 
HuH-7 Human Liver/hepatocellular carcinoma DMEM 
SK-Hep-1 Human Liver/ascite-adenocarcinoma DMEM 
SNU-449 Human Liver/hepatocellular carcinoma RPMI-1640 
SNU-387 Human Liver/hepatocellular carcinoma RPMI-1640 
SNU-398 Human Liver/hepatocellular carcinoma RPMI-1640 
SNU-475 Human Liver/hepatocellular carcinoma RPMI-1640 
SNU-182 Human Liver/hepatocellular carcinoma RPMI-1640 
FOCUS Human Liver/hepatocellular carcinoma DMEM 
Mahlavu Human Liver/hepatocellular carcinoma DMEM 
Hep3B Human Liver/hepatocellular carcinoma DMEM 
Hep3B-TR Human Liver/hepatocellular carcinoma DMEM 
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HepG2 Human Liver/hepatocellular carcinoma DMEM 
Hep40 Human Liver/hepatocellular carcinoma DMEM 
FLC4 Human Liver/hepatocellular carcinoma  DMEM 
CAMA-1 Human Mammary gland; metastatic site: pleural 
effusion adenocarcinoma 
DMEM 
MCF-7 Human Mammary gland; metastatic site: pleural 
effusion adenocarcinoma 
DMEM 
LS411N Human Cecum/colorectal carcinoma DMEM 
SW837 Human Rectum/adenocarcinoma DMEM 
U-2 OS Human Bone/osteosarcoma DMEM 
LNCaP Human  Prostate/from lymph node metastasis DMEM 
HEK293 Human Fetal kidney/transformed with 
adenovirus 5 DNA 
DMEM 
A375 Human Skin/malignant melanoma DMEM 
HeLa Human Cervix/adenocarcinoma DMEM 
MRC-5 
(p14) 
Human Fetal lung/normal DMEM 
COS-7 Monkey Kidney/SV40 transformed DMEM 
IAR 6 Rat Liver/hepatocellular carcinoma DMEM 
Ankara Bovine Lymphoblastoid/transformed with  
Theileria annulata (Ankara) 
DMEM 
Sp2 Mouse B lymphocyte/myeloma RPMI-1640 
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3.2.1.1 Thawing of Cells  
 
The vial of the cell line was taken from liquid nitrogen and immediately put on ice.  
Subsequently, the vial was put into water bath at 37 ºC and the frozen cell suspension 
was thawed. Afterwards, the cells were transferred into a 15 ml sterile tube and 10 ml 
fresh medium was gently added to the sterile tube. The cells were centrifuged at 1500 
rpm for 5 minutes at 4 ºC. The supernatant was discarded. For the anchorage-
dependent cells, the pellet was resuspended in 15 ml warm culture medium and the 
cells were plated into 150 mm culture dishes. Then, the cells were left in the tissue 
culture incubator overnight and the medium was refreshed the following day. For the 
anchorage-independent cells, the pellet was resuspended in 5 ml, 37 ºC culture 
medium and the cells were transferred to 25 cm² flask. The flask was left upright in 
the tissue culture incubator until subculturing.  
 
 
3.2.1.2. Subculturing of Cells 
 
The medium of the entire anchorage-dependent cells were refreshed every two or 
three days. They were splitted at the time when they were 80% confluent. During 
split, the medium of the dish was aspirated and the cells were washed twice with 
sterile PBS (pH 7.4). PBS was aspirated and 1.5 ml trypsin/EDTA was added to each 
150 mm dish. The cells were incubated in the tissue culture incubator for 5 minutes 
for detachment from the dish surface. Then, they were plated into appropriate 
number of new plates according to desired dilution. At the time that anchorage-
independent cells reach to the desired number, they were centrifuged at 1500 rpm for 
5 minutes at room temperature. Then, the supernatant was aspirated and the cells 
were resuspended in appropriate amount of fresh medium. When they were 
subcultured for the first time, they were transferred to a 75 cm² flask from the 25 cm² 
flask.  
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3.2.1.3. Freezing of Cells 
 
The anchorage-dependent cells were frozen when they were 60%-70% confluent in 
150 mm culture dishes. The cells were washed twice with sterile PBS after aspirating 
the medium. Then, PBS was removed, trypsin/EDTA was added for detachment and 
the dish was put into tissue culture incubator to facilitate detachment. The detached 
cells were collected and transferred to a 15 ml sterile tube. 10 ml fresh medium was 
added and the cells were centrifuged at 1500 rpm for 5 minutes at 4 ºC. The 
supernatant was discarded and the cells were resuspended in 1 ml freezing medium 
containing 20% FCS, 10% DMSO and 70 % medium (DMEM or RPMI-1640). The 
cells were transferred into a vial and the vial was immediately placed on ice. Then, it 
was put into -80 ºC. The vial was moved to liquid nitrogen tank in three days. The 
suspension cells were directly transferred into a 15 ml sterile tube and centrifuged at 
1500 rpm for 5 minutes at 4 ºC. The supernatant was discarded and the cells were 
resuspended in freezing medium containing 90% FCS and 10% DMSO. The next 
steps were the same of freezing steps of anchorage-dependent cells.  
 
 
Phosphate-Buffered Saline (PBS): 
 
10X Stock Solution       
 
80 g NaCl       
2 g KCl 
7.64 g Na2HPO4.2H2O 
2 g KH2PO4 
 
 
3.2.2. Protein Extraction from Cells 
 
The anchorage-dependent cells in the tissue culture facility were grown to be as 
confluent as 80%- 90%. Their medium was aspirated and the cells were washed 
twice with ice-cold PBS. Then, PBS was aspirated and cells were scraped in 1.5 ml 
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ice-cold PBS. The scraped cells were centrifuged at 1500 rpm for 5 minutes at 4 ºC. 
After centrifugation, the supernatant was removed and the pellet was either stored at 
-80 ºC to be used later or lysis was performed. For lysis, freshly prepared NP-40 lysis 
buffer was used. The pellets were resuspended in NP-40 lysis buffer that was 4 times 
the volume of the cell pellet. This mixture was incubated on ice for 30 minutes and 
later, it was centrifuged at 13000 rpm for 30 minutes at 4 ºC. Supernatant was taken 
into fresh tubes and stored at -80 ºC except a small amount taken for further step of 
protein quantification.  
 
 
NP-40 Lysis Buffer: 
 
150mM NaCl 
1.0% NP-40 
50 mM Tris (pH 8.0) 
1 Tablet protease inhibitor (Complete, EDTA-free Protease Inhibitor Cocktail 
Tablets, Roche) 
 
The final volume was brought to 7 ml with dH2O. 
 
 
3.2.3. Bradford Assay for Protein Quantification 
 
The tubes referred in Table 3.2 were prepared with a BSA stock of 1mg/ml 
concentration and the tubes in Table 3.3 were prepared with previously aliquoted 
total cell extracts. After preparation, BSA and protein samples were measured in 
spectrophotometer (Beckmann) at 595 nm visible light, no later than fifteen minutes.  
 
A standard linear curve was drawn as XY (scatter) chart type according to A595 of 
BSA standards. The protein concentrations of the samples were calculated according 
to the equation of this standard linear curve. 
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Table 3.2: Preparation of BSA samples  
 
 
 
Table 3.3:  Preparation of protein samples 
 
Tube numbers 1 2 3 4 5 6 
Sample (µl) 0 2 2 2 2 2 
ddH2O (µl) 98 98 98 98 98 98 
Bradford working (µl) 900 900 900 900 900 900 
Lysis buffer (µl) 2 - - - - - 
 
(Tube number 1 was blank in both tables.) 
 
 
Bradford Working Solution: 
 
50% Methanol (v/v) 
0.05% (w/v) Coomassie Brilliant Blue R-250 
10% (v/v) Acetic acid 
40% (v/v) dH2O 
 
The solution was kept in dark at 4 ºC. 
 
 
 
Tube numbers 1 2 3 4 5 6 7 8 
BSA stock (µl) 0 2.5 5 7.5 10 12.5 15 20 
ddH2O (µl) 100 97.5 95 92.5 90 87.5 85 80 
Bradford working (µl) 900 900 900 900 900 900 900 900 
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3.2.4. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) of Proteins 
 
The glass plates were assembled and the volume of the gel mold was determined 
according to the manufacturer’s instructions (CBS). The appropriate volume of 
polyacrylamide gel solution of resolving gel was prepared in a disposable plastic 
tube. In every Western blotting experiment, the gel solution was prepared to contain 
10% acrylamide concentration. The effective range of protein separation of a 10% 
acrylamide containing gel is between 16-68 kDa. 
 
Solution of 10% resolving gel for tris-glycine SDS-PAGE was prepared according to 
the Table 3.4. 
 
 
Table 3.4: Components of 10% resolving gel for tris-glycine SDS-PAGE 
 
Solution components Component volumes (ml) 
10% 5 10 15 20 25 30 40 50 
ddH2O 1.9 4 5.9 7.9 9.9 11.9 15.9 19.8
30% mix 1.7 3.3 5.0 6.7 8.3 10 13.3 16.7
1.5 M Tris-HCl (pH 8.8) 1.3 2.5 3.8 5 6.3 7.5 10 12.5
10% SDS 0.05 0.1 0.15 0.2 0.25 0.30 0.40 0.50
10% APS 0.05 0.1 0.15 0.2 0.25 0.30 0.40 0.50
TEMED 0.002 0.004 0.006 0.008 0.01 0.012 0.016 0.02
 
 
10% APS was freshly prepared for every experiment. 10% APS and TEMED were 
added respectively to the resolving gel solution just before the gel solution was 
poured. After addition of all of the solution components, the solution was swirled and 
poured into the gap between the glass plates without any delay. Sufficient space for 
stacking gel was left and the resolving gel was overlaid by pouring several drops of 
isobutanol. The gel was left for polymerization at room temperature in upright 
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position. After polymerization, the overlaying isobutanol was poured off and the top 
of the gel was washed several times with distilled water. The remaining water drops 
between the glass plates were dried by the edge of a paper towel. 
 
5% stacking gel solution was prepared according to Table 3.5. 
 
 
Table 3.5: Components of 5% stacking gel for tris-glycine SDS-PAGE 
 
Solution components Component volumes (ml) 
5% gel 1 2 3 4 5 6 8 10 
ddH2O 0.68 1.4 2.1 2.7 3.4 4.1 5.5 6.8 
30% mix 0.17 0.33 0.5 0.67 0.83 1 1.3 1.7 
1 M Tris-HCl (pH 6.8) 0.13 0.25 0.38 0.5 0.63 0.75 1 1.25
10% SDS 0.01 0.02 0.03 0.04 0.05 0.06 0.08 0.1 
10% APS 0.01 0.02 0.03 0.04 0.05 0.06 0.08 0.1 
TEMED 0.001 0.002 0.003 0.004 0.005 0.006 0.008 0.01
 
 
Freshly prepared 10% APS and TEMED were added as the last components to the 
stacking gel solution. Afterwards, the mixture was swirled rapidly and the solution 
was poured on top of the polymerized resolving gel. A comb of desired number of 
wells was inserted into the stacking gel forthwith, paying attention not to form air 
bubbles. The gel was left in vertical position at room temperature for polymerization. 
 
During polymerization, the samples to be loaded and the marker protein (Prestained 
Protein Molecular Weight Marker, Fermentas) were prepared by heat denaturation of 
the proteins at 100 ºC for 5 minutes in 1X SDS gel loading buffer. Following 
denaturation, the samples were placed on ice.  
 
After the polymerization of the SDS gel, the comb was removed carefully and the 
wells were washed with distilled water to remove any unpolymerized acrylamide. 
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The glass plates containing the gel were mounted to the gel apparatus and tris-
glycine electrophoresis buffer was added to the upper and bottom reservoirs. 5 to 10 
µg marker protein and 1 to 80 µg of sample proteins were loaded to the wells 
according to their predetermined order.  
 
The electrophoresis apparatus was connected to power supply. The gel was run at 80 
volts until the dye left stacking gel and then, the voltage was increased to 180 volts. 
The gel was run until the bromophenol blue of the gel loading buffer reached the 
bottom of the resolving gel. At that moment, the power supply was turned off and the 
glass plates were removed from the electrophoresis apparatus. The plates were 
separated from each other on a paper towel with the help of a spatula. The orientation 
of the gel was marked by cutting top right corner of the gel. 
 
 
30% Mix (Acrylamide and Bis-acrylamide Solution): 
 
146 g Acrylamide    
4 g Bis-acrylamide 
 
Volume was adjusted to 500 ml and the mix was filtered to get rid of air bubbles. It 
was stored at 4 ºC in dark for maximum 30 days. 
 
1.5 M Tris-HCl (pH 8.8): 
 
54.45 g Tris base 
150 ml ddH2O 
 
The pH was adjusted to 8.8 with 1 M HCl and the final volume was brought to 300 
ml with ddH2O. The solution was stored at 4 ºC. 
 
1 M Tris-HCl (pH 6.8): 
 
12 g Tris base 
60 ml ddH2O 
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The pH was adjusted to 6.8 with 1 M HCl and the final volume was brought to 100 
ml with ddH2O. The solution was stored at 4 ºC. 
 
10% SDS: 
 
10 g SDS was dissolved in ddH2O by stirring and brought to 100 ml. 
 
10% APS: 
 
1 ml 10% (w/v) solution was prepared freshly in ddH2O. 
 
1X SDS Gel Loading Buffer: 
 
3.8 ml distilled water 
1 ml 0.5 M Tris-HCl (pH 6.8) 
0.8 ml Glycerol 
1.6 ml 10% SDS 
0.4 ml 0.05% (w/v) Bromophenol blue 
0.4 ml 2 β-Mercaptoethanol (added freshly) 
 
2X SDS Gel Loading Buffer: 
 
25 ml 4X Tris-HCl/SDS (pH6.8) 
20 ml Glycerol 
4 g SDS 
2 ml 2 β-Mercaptoethanol (added freshly) 
 
dH2O was added to 100 ml. 
 
4X Tris-HCl/SDS (pH6.8) 
 
6.05 g Tris base was dissolved in 40 ml dH2O. pH was adjusted to 6.8 with 1 M HCl. 
Volume was brought to 100 ml and 0.4 g SDS was added. 
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5X Tris-Glycine Electrophoresis Buffer: 
 
15 g Tris    
72 g Glycine   
5 g SDS   
 
Volume was adjusted to 1 L with ddH2O and the buffer was stored at 4 ºC. 1X buffer 
was used as working solution. 
 
 
3.2.5. Transfer of Proteins from SDS-Polyacrylamide Gel to PVDF         
           Membrane 
 
For the transfer of the proteins from the SDS gel to PVDF membrane (Immobilon-P 
membrane, 0.45 µm, Millipore), four pieces of Whatman 3MM filter paper and a 
piece of PVDF membrane were cut as the same dimensions of the gel by wearing 
gloves. The membrane was left in methanol for 20 seconds, washed with distilled 
water and then soaked into transfer buffer for 15 minutes. The gel was removed from 
the glass plate and kept in transfer buffer for 10 minutes. After, it was washed with 
distilled water. Whatman 3MM papers were kept in the transfer buffer for a few 
minutes.  
 
The transfer sandwich was set on transfer unit as follows: 
 
1. 2 pieces of Whatman 3MM paper were taken out of the transfer buffer 
and placed on top of the metal transfer surface, which was the anode 
of the unit. The trapped air bubbles were driven out gently by a roller. 
2. The PVDF membrane was placed on top of Whatman 3MM papers 
aligning it exactly. Air bubbles were squeezed. 
3. The SDS gel was taken out of the transfer buffer and placed on the 
PVDF membrane. The positions of the prestained marker proteins 
were marked by a needle. Air bubbles were squeezed. 
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4. 2 pieces of Whatman 3MM paper were taken out of the transfer buffer 
and placed on top of the SDS gel. The cover was then placed on the 
unit, which was cathode. 
 
After setting, the transfer unit was connected to power supply and 3.5 mA/cm² 
current was applied to the sandwich for 45 minutes. At the end of the transfer 
process, the power supply was turned off and the sandwich was disassembled layer 
by layer from top-down.  
 
Transfer Buffer: 
 
2.9 g Glycine 
5.8 g Tris base 
0.37 g SDS 
200 ml methanol 
 
The volume was adjusted to 1 L with ddH2O. 
 
 
3.2.6. Immunological Detection of Immobilized Proteins (Western           
          Blotting) 
 
Taken from the transfer unit, the membrane was soaked into blocking solution 
composed of 3% milk powder in 0.1% Tween-20-TBS (TBS-T) solution for one hour 
at room temperature on a rotating platform. Subsequently, the membrane was 
incubated with primary antibody, which was either 6D5 or 9C11 hybridoma 
supernatant, for one hour at room temperature or overnight at 4 ºC on a slowly 
rotating platform. Following incubation, the membrane was washed with TBS-T for 
three times, once 15 minutes long and twice 5 minutes long. Next, the membrane was 
incubated with 1:5000 diluted secondary antibody (goat anti-mouse IgG-peroxidase 
conjugate, Sigma) for 1 hour at room temperature on a slowly rotating platform. 
Incubation was followed by four times washing with TBS-T, once for 15 and three 
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times for 5 minutes. Finally, the membrane was washed with distilled water and 
became ready for development.  
 
For detection of proteins immobilized on the membrane, ECL detection system 
(Enhanced Chemiluminescence, Amersham Pharmacia Biotech.) was used according 
to manufacturer’s instructions. 
 
 
10X Tris-Buffered Saline (TBS): 
 
12.19 g Tris base 
87.76 g NaCl 
 
The final volume was brought to 1 L with ddH2O and the pH was adjusted to 8 with 
1 M HCl. 1X solution was used as working buffer. 
 
 
3.3 . Immunoperoxidase Staining of Paraffin-Embedded Liver    
  Cancer Tissue Samples  
 
Three paraffin-embedded liver cancer tissue samples were cut 4 µm thick and placed 
on slides. Those samples were named as S1, S2 and S3. 
 
Immediately after sectioning, tissue samples were left in 70 ºC oven for 20 minutes 
for deparaffinization of the tissues. Then, deparaffinization was continued on the 
bench. The samples were taken into xylene for 5 minutes, 99% ethanol for 5 minutes, 
90% ethanol for 5 minutes, 70% ethanol for 5 minutes, 50% ethanol for 5 minutes, 
and distilled water for 5 minutes, respectively. Next, antigen retrieval step was 
applied. The samples were placed in pre-warmed citric acid (pH 6) in a glass plate 
and the glass plate was transferred to a plastic container of warm water. Then, the 
plastic container was moved into microwave oven that was set to 750 W. The citric 
acid solution was allowed to boil for 15 minutes and its level was checked against 
evaporation and plates were refilled whenever necessary. At the end of 15 minutes, 
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the plastic container was taken out of microwave oven and left at room temperature 
for cooling. Next, the slides were soaked in distilled water for five minutes and then, 
washed 3 times (5 minutes for each) with TBS (pH 8). Afterwards, the slides were 
immerged in 5% Triton X-100 containing 3% hydrogen peroxide for inhibition of 
endogenous peroxidase activity in the tissues. 20 minutes later, slides were washed 3 
times with TBS, each washing step lasting 5 minutes. Then, blocking was performed 
to prevent binding of the reagents to the unspecific sites in the tissues. 1.5% goat 
serum in TBS was dropped on each slide covering whole tissue and the slides were 
incubated for 1 hour at room temperature. 6D5 or 9C11 antibody was used as 
primary antibody and the slides were incubated with either of them for 1 hour at 
room temperature or overnight at 4 ºC after blocking. If the antibodies were to be 
diluted, blocking solution was used. Primary antibody step was followed by 3 times 
washing with TBS for 5 minutes for each. On the next step, biotinylated link and 
streptavidin-HRP reagents (LSAB2 System, Dako) were used according to the 
product information of the supplier. This step was followed by 3 times washing with 
TBS, 5 minutes each. Then, liquid DAB/Chromogen reagent kit (Dako) was applied 
to the samples according to the manufacturer’s recommendations. Counter staining 
of the samples was performed with hematoxylene as long as the tissues were 
apparently stained (30 seconds to a few minutes). Excess of the hematoxylene was 
washed away with tap water and cover slips were mounted on the slides with 
glycerol.  
 
 
Citric Acid (pH 6): 
 
3.8 g citric acid was dissolved in 1.9 L dH2O and the pH was adjusted to 6 with 2 M 
NaOH. Final volume was adjusted to 2 L. 
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4. RESULTS  
 
4.1. Production of 6D5 and 9C11 Monoclonal Antibodies 
 
Balb/c mice was immunized with apoptosis induced (by UV-C irradiation, 60-120 
mJ/cm²) hepatocellular carcinoma cell line HuH-7. Hybridomas were prepared from 
the spleen cells of the sacrificed mice (performed by T. Yagci). Among 22 of 
monoclonal antibody-producing clones selected, 2 were named as 6D5 and 9C11, 
and were used for further studies. 
 
 
4.2. Biochemical Characterization of 6D5 and 9C11 Monoclonal 
Antibodies 
 
Twenty eight different cell lines (Table 3.1) were used to investigate whether 6D5 or 
9C11 monoclonal antibody reacted with an epitope present in any of those selected 
cell lines. Fourteen of the selected cell lines were hepatocellular carcinoma, two of 
them were breast carcinoma, two were colorectal carcinoma, one was osteosarcoma, 
one was prostate carcinoma, one was fetal kidney carcinoma, one was malignant 
melanoma, one was cervical cancer, one was normal fetal lung, one was transformed 
monkey kidney, one was rat hepatocellular carcinoma, one was transformed bovine 
lymphoblastoid, and one was mouse myeloma cell line. The cell lines apart from 
human origin were selected for validation of cross-species reactivity of 6D5 and 
9C11 antibodies. 
 
All of the cell lines were grown, as confluent as they should be, in 150 mm dishes. 
The cells were scraped to obtain cell pellets and their total cell lysates were prepared 
by using NP-40 lysis buffer. The total cell lysates were loaded to 10% SDS gel. The 
loaded amounts of the total cell lysates are mentioned in sections 4.2.1 and 4.2.2. 
Convenient transfer buffers were used to transfer proteins from SDS gels to PVDF 
membranes. The membranes were subjected to Western blotting either with 6D5 or 
9C11 antibody. 
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4.2.1 Western Blotting With 6D5 Antibody 
 
First, a panel of 9 different HCC cell lines was used in Western blotting with 6D5 
antibody. Figure 4.1 displays banding pattern of those cell lines when 10 µg protein 
containing total cell lysate was loaded to each well. Hep3B (lane 4), SNU-475 (lane 
5), and SK-Hep-1 (lane 7) cell lines revealed a similar banding pattern including an 
upper band, around 75 kDa, and a lower band just below that one. However, the 
equal loading control, which was performed with anti-calnexin antibody, revealed 
that the total amount of protein extract from SK-Hep-1 cell line loaded to the SDS 
gel was much more less than those of Hep3B and SNU-475. On the contrary, the 
signal intensity of the bands belonging to SK-Hep-1 cell line was no weaker than 
those of Hep3B and SNU-475. It seemed that Hep3B and SNU-475 cell proteins 
were equally loaded to the SDS gel. In Hep3B and SK-Hep-1 cell lines, both of the 
upper and lower bands seemed to be of equal density when upper was compared to 
lower one, but the upper band observed in SNU-475 was more intense than the lower 
band of the same cell line. HuH-7 (lane 1), HepG2 (lane 2), SNU-182 (lane3), Hep40 
(lane 8) and SNU-398 (lane 9) cell lines exhibited single banding pattern. However, 
there were some apparent differences between those cell lines. HuH-7, Hep40 and 
SNU-398 cell lines expressed a band that is at the same molecular weight with the 
lower band of Hep3B, SNU-475 and SK-Hep-1 cell lines. Although total amount of 
loaded HuH-7 protein seemed to be more than those of Hep40 and SNU-398, it had 
weaker band intensity. On the other hand, HepG2 and SNU-182 cell lines expressed 
a band that is at the same molecular weight with the upper band of Hep3B, SNU-475 
and SK-Hep-1 cell lines. HepG2 seemed to be equally loaded with HuH-7 and it 
displayed the same band intensity with HuH-7 but, total amount of cell protein of 
SNU-182 was slightly less loaded than those of HepG2 and Huh-7. In addition, it 
was slightly weaker in terms of band intensity. Hep3B-TR (lane 6) cell line displayed 
a completely different banding pattern from the previously mentioned cell lines. The 
amount of protein loaded from Hep3B-TR total cell lysate seemed definitely more 
than that of SK-Hep-1 but it was less than those of the rest of the cell lines. On the 
contrary, Hep3B-TR had a very dense, smear-like banding pattern. The signal 
intensity of Hep3B-TR was the strongest among those 9 hepatocellular carcinoma 
cell lines. 
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Figure 4.1: 6D5 Western blotting with 9 different HCC cell lines. Expression 
patterns of Huh-7, HepG2, SNU-182, Hep3B, SNU-475, Hep3B-TR, SK-Hep-1, 
Hep40 and SNU-398 cell lines are displayed. 
 
 
Next, 4 different HCC cell lines were subjected to Western blotting. In Figure 4.2, 
the banding pattern of those cell lines are displayed each of which contained 10 µg 
protein while loading. According to the pattern of equal loading with anti-calnexin 
antibody, all the total cell proteins were equally loaded. In addition to this, signal 
intensities of all of the cell lines were equal to each other. However, there were some 
differences between the banding patterns. FOCUS (lane 1) cell line had two-banding 
pattern as Hep3B, SNU-475 and SK-Hep-1 cell lines did. Contrarily, band intensities 
of those upper and lower bands were different. FOCUS cell line was the only one 
with an upper band weaker than its lower counterpart among the HCC cell lines 
representing a two-banding pattern. SNU-387 (lane 2) pictured a totally different 
band with a molecular weight around 40 kDa, which was observed in none of the 
other cell lines. Each of SNU-449 (lane 3) and Mahlavu (lane 4) cell lines exhibited a 
single band at the same molecular weight with the lower band of FOCUS cell line. 
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Figure 4.2: 6D5 expression pattern of 4 different HCC cell lines. Western blotting 
was performed with FOCUS, SNU-387, SNU-449, and Mahlavu cell lines. 
 
                                                                                                                                      
Then, Western blotting study was broadened by the addition of different cell lines of 
liver and non-liver origin to the experiments (Figure 4.3). In this panel of study, 
HuH-7 (lane 1) cell line was used as positive control and SNU-387 (lane 3) was 
included for its interesting banding pattern that was observed in Figure 4.2. The 
amount of the loaded protein was increased to 20 µg per well since we wanted to 
question the presence of any bands other than the ones we previously detected. Equal 
loading with anti-calnexin antibody revealed that all of the samples were equally 
loaded. HuH-7 cell line displayed the expected banding pattern confirming the 
previous experiments. FLC4 (lane 2) cell line did not exhibit any bands although it 
was an HCC variant. Therefore, it was unique with this property among the human 
HCC cell lines used in this study. Interestingly, SNU-387 cell line represented a 
different band than the one it displayed before and this band was at the same 
molecular weight as the band observed in HuH-7. Moreover, A375 (lane 4) and 
HeLa (lane 7) cell lines had a banding pattern similar to that of HuH-7. However, it 
was questionable whether HeLa contained a second band below 50 kDa, whose 
expression was also observed in U-2 OS (lane 8) and LNCaP (lane 9) cell lines. U-2 
OS and LNCaP cell lines revealed the same banding pattern, LNCaP expressing 
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weaker bands. Although not very clear, HEK293 (lane 5) seemed to display two very 
near bands, one of which migrated at the same level with band of HuH-7 and the 
other located slightly lower than this one. MRC-5 (lane 6) cell line had a differential 
banding pattern with an unusual band just above 50 kDa and one at the same 
molecular weight with band of HuH-7. 
 
 
    
          
 
 
 
 
Figure 4.3: 6D5 Western blotting with cell lines from 7 different tissues-20 µg.  
Banding patterns of HuH-7, FLC4, SNU-387, A375, HEK293, MRC-5, HeLa, U-2 
OS, and LNCaP cell lines with 6D5 monoclonal antibody are displayed. 
 
 
Figure 4.4 involves the same panel of cell lines as Figure 4.3 but this time 50 µg 
protein was loaded per well since we wanted to clarify the picture of banding pattern. 
The equal loading was performed with anti-calnexin antibody. The entire cell lines 
were equally loaded, except LNCaP (lane 9), which was over-loaded. HuH-7 (lane 1) 
and FLC4 (lane 2) cell lines corroborated their banding pattern. SNU-387 (lane 3) 
clearly displayed two bands, one of which was previously displayed in Figure 4.2 
and the other in Figure 4.3. The lower one of those bands that was below 50 kDa was 
much denser than the upper one that was around 75 kDa. The probable reason that 
this denser band was absent but the weaker one was present in Figure 4.3 could be a 
transfer problem in the membrane. It was observed that A375 (lane 4) cell line 
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represented two bands, one of which was absent from Figure 4.3. This newly 
observed band was at the same molecular weight with the upper band of  SNU-475, 
SK-Hep-1 and FOCUS cell lines. The upper band of A375 was expressed weaker 
than its lower counterpart. HEK293 (lane 5) was far from displaying two bands it 
used to display in Figure 4.3 concluding that 50 µg of protein load was too much for 
it for a clear banding pattern. Unlike its profile in Figure 4.3, the banding pattern of 
MRC-5 (lane 6) cell line was clearly displayed as three equally intense bands. The 
two upper bands of MRC-5 were at the same molecular weight with the two bands of 
A375 cell line. With the help of 50 µg of protein load, we figured out that the band 
around 40 kDa, which we were suspicious about its presence, was expressed in HeLa 
(lane 7). Both of the upper and lower bands of HeLa represented a profile just the 
same as that of SNU-387. Moreover, both of the upper bands of those cell lines were 
weaker when compared to their lower counterparts. It was revealed that 50 µg of 
protein load was excessive for a clear figure of U-2 OS (lane 8) cell line. As a result 
of overload, it lost its clear two banding pattern but instead had a smear-like banding. 
In lane 9, there seems to be a problem in transfer affecting the banding pattern of 
LNCaP cell line.  
 
        
        
 
 
 
 
Figure 4.4: 6D5 Western blotting with cell lines from 7 different tissues-50 µg. 
Banding patterns of HuH-7, FLC4, SNU-387, A375, HEK293, MRC-5, HeLa, U-2 
OS, and LNCaP cell lines are displayed. 
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The cell line panel of Figure 4.5 is composed of both human and non-human origin 
cell lines. HuH-7 (lane 1) was included to the panel as positive control. The equal 
loading was performed with anti-calnexin antibody indicating equal loading of the 
samples except LNCaP (lane 11), which was slightly overloaded. There were no 
bands in IAR (rat), Ankara (bovine), COS-7 (monkey) and Sp2 (mouse) cell lines 
(lane 2, lane 3, lane 4 and lane 5, respectively) indicating that 6D5 was human 
specific, thus it did not display cross-species reactivity. Furthermore, none of 
LS411N (lane 6) or CAMA-1 (lane 8) cell lines displayed any bands even though 
they were of human origin. SW837 (lane 7) exhibited only one band that was at the 
same molecular weight and equally dense with that of HuH-7. MCF-7 (lane 9) 
represented only one band that was at the same molecular weight with the lower 
band of SNU-387, LNCaP, U-2 OS and HeLa cell lines. U-2 OS (lane 10) and 
LNCaP cell lines displayed the same cloudy banding pattern as in the Figure 4.4 
since 50 µg of protein load was excessive for them. 
 
  
 
 
 
 
 
 
Figure 4.5: 6D5 expression analysis of human and non-human origin cell lines. 
Western blotting pattern of HuH-7, IAR 6, Ankara, COS-7, Sp2, LS411, SW837, 
CAMA1, MCF-7, U-2 Os and LNCaP cell lines with 6D5 monoclonal antibody is 
displayed. 
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The fact that Hep3B-TR cell line differs from Hep3B being resistant to growth 
inhibition by transforming growth factor β1 (TGF-β1) directed us to the idea that it 
might be interesting to see the differences in the expression pattern of those cell 
lines. Therefore, we aimed to verify the differential banding pattern of Hep3B and 
Hep3B-TR, which was demonstrated in Figure 4.1. Figure 4.6 displays the banding 
pattern of serially diluted protein loads of Hep3B and Hep3B-TR cell lines. The 
loaded protein amount was 50 µg for the lanes 1 and 2, 25 µg for the lanes 3 and 4, 
10 µg for the lanes 5 and 6, and 5 µg for the lanes 7 and 8. The lanes 5 and 6 
revealed the clearest banding patterns with 3 bands displayed by Hep3B and 2 bands 
displayed by Hep3B-TR. Those banding patterns of Hep3B and Hep3B-TR were 
totally different from their previous banding patterns. In Figure 4.1, Hep3B displayed 
two bands with equal densities and Hep3B-TR displayed a smear-like banding 
pattern without a clear view of the number of its bands. In this figure, one of the 
three bands of Hep3B, which was around 75 kDa, was more intense than its other 
two counterparts of equal density. In addition, it was revealed that Hep3B-TR had 2 
clear bands at the same molecular weight with two upper bands of Hep3B. The upper 
band of Hep3B-TR was denser than its lower counterpart and than its counterpart in 
Hep3B. On the other hand, the lower band of Hep3B-TR was lighter than its 
counterpart in Hep3B. 
 
 
  
    
 
 
 
 
 
Figure 4.6: Differential expression of Hep3B and Hep3B-TR cell lines with 6D5. 
Serially diluted Hep3B and Hep3B-TR protein extracts were loaded to the wells.  
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4.2.2 Western Blotting with 9C11 Antibody 
 
The first of Western blotting experiments with 9C11 was performed with 5 HCC cell 
lines. Figure 4.7 displays Western blotting panel of those cell lines using 80 µg total 
protein extract. The entire cell lines, namely HuH-7 (lane 1), SNU-398 (lane 2), 
Hep3B (lane 3), SNU-449 (lane 4), and HepG2 (lane 5), exhibited a single banding 
pattern around 75 kDa. It was revealed that this band was different from the one that 
was displayed with 6D5 (data not shown). The equal loading control performed with 
anti-calnexin antibody showed that HuH-7 and Hep3B were equally loaded, SNU-
398 was overloaded than those two, and SNU-449 and HepG2 were loaded less than 
HuH-7 and Hep3B. In spite of containing least amount of protein loads, SNU-449 
and HepG2 had clear, strong banding profiles. The other three cell lines had denser 
bands correlating with their amount of loaded protein. 
 
 
                     
 
       
 
 
 
Figure 4.7: 9C11 Western blotting with 5 different HCC cell lines. Expression 
pattern of HuH-7, SNU-398, Hep3B, SNU-449 and HepG2 cell lines is displayed. 
 
 
Western blotting experiments with 9C11 antibody was continued with a broader 
panel of HCC cell lines (Figure 4.8). In Figure 4.8, each well contained 50 µg total 
protein extract of Mahlavu (lane 1), SNU-182 (lane 2),   SNU-387 (lane 3), Hep3B-
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TR (lane 4), Hep40 (lane 5), FOCUS (lane 6), SK-Hep-1 (lane 7), and SNU-475 
(lane 8) cell lines, respectively. The equal loading was performed with anti-GSK-3β 
antibody. GSK-3β pattern revealed that SNU-182, Hep3B-TR, FOCUS, SK-Hep-1 
and SNU-475 cell lines were equally loaded but Mahlavu was a little more loaded, 
and SNU-387 was slightly less loaded when compared to the equally loaded cell 
lines. Hep40 was loaded with least amount of protein among entire cell lines. All the 
cell lines displayed a band around 75 kDa, likewise the expression pattern of the cell 
lines in Figure 4.7. Considering the equal loading pattern of all cell lines, Hep40 had 
a strong band contrary to its small amount of protein load when compared to the 
other cell lines. Likewise, SNU-182 and SNU-387 cell lines displayed dense bands 
when we considered their protein load. On the other hand, Hep3B-TR, FOCUS, SK-
Hep-1 and SNU-475 cell lines had similar band intensities with 9C11 blotting as they 
did with anti-GSK-3β blotting. Mahlavu had the strongest band in equal loading 
however; it did not exhibit a band as strong as SNU-182 did.  
 
 
  
  
 
 
 
 
Figure 4.8: 9C11 expression pattern of 8 different HCC cell lines. Western 
blotting of Mahlavu, SNU-182, SNU-387, Hep3B-TR, Hep40, FOCUS, SK-Hep-1 
and SNU-475 cell lines is displayed. 
 
 
Like that of 6D5 antibody, 9C11 Western blotting panel of studied cell lines was 
extended to include both liver and non-liver origin cell lines. According to this, 
Figure 4.9 displays the banding pattern of HuH-7 (lane 1), FLC4 (lane 2), SNU-387 
(lane 3), A375 (lane 4), HEK293 (lane 5), MRC-5 (lane 6), HeLa (lane 7), U-2 OS 
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(lane 8) and LNCaP (lane 9) cell lines. HuH-7 was included to the panel as positive 
control and SNU-387 was added to question its previous expression profile in Figure 
4.8 because this cell line had an interesting outcome with 6D5 antibody. 50 µg total 
cell protein was loaded to each well. The equal loading was done with anti-calnexin 
antibody. Apart from LNCaP cell line, whose protein was slightly overloaded, the 
protein samples were equally loaded. As seen in the figure, every cell line expressed 
a band around 75 kDa similar to the ones in Figure 4.7 and Figure 4.8. In this panel 
of cells, FLC4 was the only one lacking the expression of an epitope reacting with 
9C11. SNU-387, A375, HEK293, MRC-5, HeLa, and U-2 OS cell lines, which were 
equally loaded, had nearly the same band intensities. Contrary to this, LNCaP 
displayed the weakest banding of all although it contained the most amount of 
protein in the loading. 
 
 
        
 
 
 
 
 
Figure 4.9: 9C11 Western blotting with cell lines from 7 different tissues. 
Expression profile of HuH-7, FLC4, SNU-387, A375, HEK293, MRC-5, HeLa, U-2 
OS and LNCaP cell lines is displayed. 
 
 
Then, Western blotting of human and non-human origin cell lines was accomplished 
with 9C11 (Figure 4.10). In Figure 4.10, 50 µg total cell protein was loaded to each 
well and equal loading was performed with anti-calnexin antibody. Calnexin 
revealed equal band intensities in all cell lines except MCF-7 (lane 9). MCF-7 was 
slightly less loaded when compared to rest of the cell lines. IAR 6 (lane 2), Ankara 
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(lane 3), SW837 (lane 7) and MCF-7 were the cell lines that expressed a single band. 
This single band was at the same molecular weight with that of HuH-7 (lane 1). 
9C11 antibody reacted with 2 non-human origin cell lines, IAR 6 (rat) and Ankara 
(bovine), but did not react with other two, COS-7 (monkey, in lane 4) and Sp2 
(mouse, in lane 5). IAR 6 cell line displayed a weak band whereas Ankara had a 
strong band. LS411N (lane 6) and CAMA-1 (lane 8) were the two human origin cell 
lines that 9C11 seemed not to react with. SW837 exhibited the strongest band of all 
and MCF-7 had a weak signal, correlating with its equal loading band intensity, 
similar to that of IAR 6.  
 
 
      
 
 
 
Figure 4.10: 9C11 expression analysis of human and non-human origin cell 
lines. Western blotting patterns of HuH-7, IAR 6, Ankara, COS-7, Sp2, LS411N, 
SW837, CAMA-1, and MCF-7 cell lines are displayed.  
 
 
4.2.3. Banding Patterns of Cell Lines in Western Blotting With 6D5  
          and 9C11 Antibodies 
 
Table 4.1 is the banding patterns of the cell lines, prepared according to the 
expression results of 6D5 and 9C11 antibodies in Western blotting. The table also 
includes information about the studied cell lines. 
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Table 4.1: Western blotting banding patterns of the studied cell lines  
 
Cell Line Organism Tissue/Cancer Type Morphology Differentiation Status Banding Pattern/Intensity 
         6D5 9C11 
HuH-7 Human Liver/hepatocellular carcinoma Epithelial Differentiated b,++ ++ 
SK-Hep-1 Human Liver/ascite-adenocarcinoma Epithelial  (endothelial origin) Poorly differentiated a,+++; b,+++ + 
SNU-449 Human Liver/hepatocellular carcinoma Epithelial   b,++ ++ 
SNU-387 Human Liver/hepatocellular carcinoma Epithelial  (pleiomorphic)   b,+; e,++ ++ 
SNU-398 Human Liver/hepatocellular carcinoma Epithelial   b,+++ + 
SNU-475 Human Liver/hepatocellular carcinoma Epithelial   a,++; b,+ + 
SNU-182 Human Liver/hepatocellular carcinoma Epithelial   a,+ ++ 
FOCUS Human Liver/hepatocellular carcinoma Epithelial   a,+; b,++ + 
Mahlavu Human Liver Epithelial  Poorly/moderately diff. b,++ + 
Hep3B Human Liver/hepatocellular carcinoma Epithelial Well differentiated a,++; b,++; c++ + 
Hep3B-TR Human  Liver/hepatocellular carcinoma Epithelial    a,+++; b,++ + 
HepG2 Human Liver/hepatocellular carcinoma Epithelial Well differentiated a,++ ++ 
Hep40 Human  Liver  Epithelial   b, + +++ 
FLC4 Human Liver/hepatocellular carcinoma  Epithelial    Ø Ø 
 - 57 -
CAMA-1 Human Mammary gland; metastatic site: pleural effusion adenocarcinoma Epithelial Poorly differentiated 
Ø Ø 
MCF-7 Human Mammary gland; metastatic site: pleural effusion adenocarcinoma Epithelial Differentiated 
e,++ + 
LS411N Human Cecum/colorectal carcinoma Epithelial Poorly differentiated Ø Ø 
SW837 Human Rectum/adenocarcinoma Epithelial Poorly differentiated  b,++ +++ 
U-2 OS Human Bone/osteosarcoma Epithelial Moderately differentiated  
b,++; e,+++; and 
some unusual 
banding 
patterns? 
++ 
LNCaP Human Prostate/from lymph node metastasis Epithelial Differentiated  b,+; e,++ + 
HEK293 Human Fetal kidney/transformed with adenovirus 5 DNA Epithelial   
a,++; b,++ ++ 
A375 Human Skin/malignant melanoma Epithelial   a,+; b,++ ++ 
HeLa Human Cervix/adenocarcinoma Epithelial   b,+; e,++ ++ 
MRC-5 p14 Human Fetal lung/normal  Fibroblast   a,++; b,++; d,++ ++ 
COS-7 Monkey Kidney/SV40 transformed Fibroblast   Ø Ø 
IAR 6 Rat Liver/hepatocellular carcinoma Epithelial    Ø + 
Ankara Bovine Lymphoblastoid/transformed with  Theileria annulata (Ankara)  Lymphoblastoid   
Ø ++ 
SP2 Mouse B lymphocyte/myeloma Lymphoblast   Ø Ø 
 
* a, refers to the band slightly above 75 kDa; b, refers to the band around 75 kDa, c, refers to the band just below 75 kDa; d, refers to the band 
just above 50 kDa; e, refers to the band below 50 kDa.
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4.3. Immunohistochemistry with 6D5 and 9C11 Antibodies 
 
After Western blotting experiments, we examined in vivo reactivity of 6D5 and 9C11 
antibodies in three different paraffin-embedded liver carcinoma tissue samples. 
Paraffin-embedded carcinoma biopsy samples were cut 4 µ thick and named as S1, 
S2 and S3. Immunoperoxidase assay was performed as described in Materials and 
Methods. The pictures of the slides were taken under Zeiss light microscope by 
Kodak digital photograph machine. The most informative magnifications are 
demonstrated on the next pages. The white arrows on the images indicate a negative 
staining and the black arrows indicate a positive staining. 
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(Black arrows indicate positive staining, white arrows indicate negative staining.) 
 
 
Figure 4.11: Immunoperoxidase stainings of paraffin-embedded liver carcinoma 
tissue sample S1. A. Control sample (25X). Immunoperoxidase staining was 
performed without primary antibody.   B. Immunoperoxidase staining with 9C11 at 
50X. The upper part of the encapsulated liver tissue was composed of cirrhotic cells 
and the bottom part was composed of tumor cells. 9C11 seemed to stain neither of 
those pathological areas. C. Immunoperoxidase staining of S1 with 6D5 at 50X. 6D5 
stained an area that was composed of cirrhotic cells but the tumor cells at the bottom 
right were not stained. D. A larger view (200X) of the positively stained cirrhotic 
cells. The neighboring tumor cells were not stained.  
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Figure 4.12:  Immunoperoxidase stainings of paraffin-embedded liver 
carcinoma tissue sample S2. Most probably, there is an underlying secondary 
biliary cirrhosis in S2. Both of the images have 200X magnification. A. 9C11 was 
used as negative control since it did not stain previously studied paraffin-embedded 
liver tissue samples. In this section, the tissue was crowded with cirrhotic nodules of 
biliary tract. B. Immunoperoxidase staining with 6D5. The cirrhotic nodules of 
hepatocytes and cirrhotic biliary tract epithelium were both stained. 
 
 
 
 
    
 
 
Figure 4.13: Immunoperoxidase stainings of paraffin-embedded liver carcinoma 
tissue sample S3. A. Staining with 9C11 was used as negative control. 
Magnification was 50X. B. The section in the view was composed of tumor cells 
stained with 6D5 at 100X. 
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5. DISCUSSION AND FUTURE PERSPECTIVES 
 
In the multistep progression of cancer, it is not known how many genes are expressed 
differentially in tumor versus normal cells. In addition to this, it is not clear whether 
these differential changes are tumor-specific or cell type-specific (Lin and Wei, 
1997). Therefore, a better insight into understanding malignancy would reveal the 
genes and their products that may be useful as prognostic, diagnostic and therapeutic 
markers. 
 
An ideal tumor marker should be highly specific in terms of cancer and tissue type, 
should be present in detectable amounts in the patient even in the early stages of the 
malignancy, and should reflect the tumor grade. However, very few, if any, markers 
might fulfill those requirements. The most common limitation of the tumor markers 
is lack of specificity; many of the markers are not tumor-specific but tumor-
associated. That means, they are elevated in more than one cancer type and even in 
some benign or physiological conditions. Besides, the potential role of tumor 
markers is precluded by the fact that most of them are not limited to the cancerous 
cell type.  Those facts usually restrict the use of tumor markers. The diagnostic, 
prognostic or therapeutic role of a marker generally results from its differential 
characteristics in malignant versus benign or malignant versus normal phenotype. 
(White et al., 2001; http://lwwoncology.com). 
 
6D5 and 9C11 are mouse monoclonal antibodies that are produced against apoptosis 
induced hepatocellular carcinoma cells. Apparently, they react with different 
epitopes that are present in a wide panel of cell lines. 6D5 and 9C11 display a 
differential banding profile in Western blotting in addition to their differential 
immunoperoxidase staining profiles in tumor tissue sections. 
 
6D5 antibody does not react with protein extracts of COS-7 (monkey), IAR 6 (rat), 
Sp2 (mouse) and Ankara (bovine) cell lines. As a result, 6D5 seems to react only 
with human proteins but not with the cell proteins of non-human species. In addition 
to cell lines mentioned above, 6D5 does not react with FLC4, CAMA-1 and LS411N 
cell proteins. FLC4 is the only hepatocellular carcinoma cell line that 6D5 does not 
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react with. The underlying reason may be the fact that FLC4 is a cell line, established 
by cloning JHH-4 hepatocellular carcinoma cells (Aoki et al., 1998) expressing low 
levels of AFP. This feature resembles the characteristic of FLC variant of HCC, 
which is a moderate, highly curable tumor type when detected and resected in the 
early stages of the tumor development. DeVita et al. (2001) describes the distinct 
appearance and clinical behavior of the fibrolamellar variant as the most important 
pathologic issue of HCC. Unlike HCC, fibrolamellar carcinoma is not invasive but 
well circumscribed, more frequent in young women (median age of the patiens is 23 
years), highly resectable, naturally occurs in the absence of underlying cirrhosis, and 
it is AFP and hepatitis B negative. It also generally exhibits a slower clinical course 
than the more common HCC. Among those features, absence of underlying cirrhosis 
should be mentioned because in our study, immunoperoxidase staining of liver 
carcinoma tissue samples displayed positive staining in cirrhotic areas with 6D5 
antibody. This finding correlates with the negative banding pattern of FLC4 cell line 
in Western blotting unlike the other 13 HCC-derived cell lines.  
 
CAMA-1 cell line originates from breast adenocarcinoma just the same as MCF-7 
does. However, 6D5 has positive result with MCF-7 in Western blotting. The 
apparent difference between those cell lines is their differentiation status. CAMA-1 
is a poorly differentiated cell line, whereas MCF-7 is a differentiated one. 6D5 may 
be reacting with a protein that is down-regulated during dedifferentiation of breast 
tumor cells in the process of cancer progression.  
 
Among the two colorectal carcinoma cell lines, LS411N originates from cecum and 
SW837 originates from rectum. 6D5 is not immunoreactive to LS411N cell protein 
but immunoreactive to SW837 cell protein. Both of those colorectal carcinoma cell 
lines are poorly differentiated therefore, their differential expression pattern in 
Western blotting seems to result from molecular differences between cecum and 
rectal carcinomas. 
 
6D5 displays differential positive banding patterns for Hep3B and Hep3B-TR 
isogenic cell lines. Hep3B-TR cell line differs from Hep3B in terms of being 
resistant to TGF-β1 because it lacks TGF-βRII gene. Since TGF-β mediates cell 
proliferation, growth inhibition and differentiation, absence of TGF- βRII leads to a 
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cell line that is resistant to the growth-inhibitory effect of TGF-β1. On the contrary, 
Hep3B is sensitive to growth inhibition by TGF-β (Inagaki et al., 1993). Therefore, 
the differential expression pattern of those cell lines in Western blotting most 
probably results from their difference in the presence of TGF-βRII gene. 
 
When we evaluate the banding pattern of the whole cell lines, it is observed that 6D5 
has a multiple-banding profile in contrast to single-banding profile of 9C11. Overall, 
there are five different bands appearing in Western blotting with 6D5 antibody. The 
probable cause may be the presence of alternatively spliced forms of the protein that 
6D5 reacts with. In many cancers, malignant transformation includes aberrant 
functioning of tumor-specific truncated proteins or deregulation of expression of 
critical proteins. One of the examples is tumor marker PSMA and its regulation in 
prostate cancer. PSMA is alternatively spliced to produce at least three variants. One 
of those alternatively spliced forms is truncated from its transmembrane region. 
Therefore, the elevated level of this truncated form of PSMA in the serum of an 
individual is related to prostate cancer development (Ghosh and Heston, 2004).  
 
Among the cell lines that display positive banding pattern; HuH-7, SNU-449, SNU-
398, Mahlavu, Hep40, and SW837 cell lines exhibit a single band around 75 kDa. 
The band intensities of HuH-7, SNU-449, Mahlavu and SW-837 cell lines are equal. 
SNU-398 has the strongest band intensity, whereas Hep40 has the weakest. SK-Hep-
1, SNU-475, FOCUS, Hep3B- TR, HEK293, and A375 cell lines display a double- 
banding pattern. One of those bands is around 75 kDa and the other is just above this 
band. The band intensities of those cell lines vary from one another and also between 
two bands of the same cell line.  
 
SNU-182 and HepG2 cell lines represent a single band just above 75 kDa, HepG2 
expressing a denser band.  
 
SNU-387, LNCaP, and HeLa cell lines have a double-banding pattern. U-2 OS may 
be included to this group but we are not very sure whether it displays some additional 
bands. The multiple, smear-like banding pattern of U-2 OS may be as a result of the 
amplification of the gene product that 6D5 is immunoreactive to. The upper band 
displayed by those cell lines is around 75 kDa whereas the lower band is around 40 
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kDa. The band intensities of those cell lines are different from each other and the 
upper and lower bands have different strength of expression.  
 
Hep3B cell line is unique with its banding profile. The lowest of the three bands 
displayed by Hep3B is observed in none of the rest of the cell lines.  
 
MCF-7 is another cell line whose banding profile is unique. MCF-7 expresses only a 
single band that is around 40 kDa.  
 
MRC-5 also displays a banding pattern different from the other cell lines. It exhibits 
3 bands, the lowest of which is just above 50 kDa. This band is not present in the 
other cell lines. The differential banding pattern of MRC-5 may depend on either the 
fibroblastic or normal (mortal) feature of this cell line. In addition, MRC-5 is 
established from fetal lung, which is worth to consider for evaluation of oncofetal 
properties of the detected protein. The banding patterns of the cell lines are 
summarized in Table 4.1. 
 
The positive results of Western blotting with 9C11 antibody always display a single-
banding pattern. This single band has a molecular weight around 75 kDa. In addition, 
the band intensities of the positive cell lines are not as diverse as that of 6D5.  
 
9C11 does not react with neither of FLC4, CAMA-1, LS411N, COS-7 or Sp2 cell 
lines. It is very probable that the reason of this non-immunoreactivity is the same as 
the reason of non-immunoreactivity of 6D5 with those cell lines. FLC4 is a moderate 
variant of JHH-4 cell line resembling the FLC variant of HCC with some of its 
molecular features, CAMA-1 is poorly differentiated when compared to MCF-7, 
LS411N originates from cecum of colon, probably displaying different molecular 
pathogenesis from SW837 cell line of rectum adenocarcinoma, and COS-7 and Sp2 
cell lines are of non-human origin, which we naturally do not expect to react with 
9C11. 
 
Contrary to 6D5, 9C11 reacts with IAR 6 and Ankara cell lines leading to cross-
species reactivity. It is surprising that 9C11 reacts with an epitope present in rat and 
bovine but absent from mouse (Sp2) and monkey (COS-7). Since 9C11 reacts with 
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rat and bovine cell proteins, it would be expected to react with monkey cell proteins 
in terms of phylogenic relation. However, 9C11 does not display this expected 
profile in Western blotting experiments.   
 
Apart from FLC4, CAMA-1, LS411N, COS-7 and Sp2 cell lines, 9C11 reacts with 
all of the studied cell lines. 
 
Immunoperoxidase experiments performed with paraffin-embedded liver carcinoma 
tissues reveal a differential staining pattern among 6D5 and 9C11 antibodies. No 
significant staining is observed with 9C11 concluding that 9C11 cannot recognize its 
epitope in those paraffin-embedded liver tissue samples in our experimental 
conditions. One of the reasons may be the limitations of routinely processed paraffin-
embedded tissue sections in terms of preserving the antigenic determinants of the 
molecules (Shi et al., 1997). Although our immunoperoxidase experiments involved 
an antigen retrieval step to increase the sensitivity and to decrease background 
staining in the samples, masking of the antigens in the paraffin-embedded tissue 
samples is very common in daily applications of immunohistochemistry. 
 
 
On the other hand, 6D5 antibody has positive staining in all of the three samples. An 
interesting outcome is the staining of cirrhotic hepatocytes and cirrhotic cells of bile 
duct epithelium in addition to staining of some tumor cells. Cirrhosis is one of the 
most important factors underlying HCC; 90% of the HCC cases develop from 
cirrhotic liver (Alberts et al., 2001). Chronic hepatitis is the major cause of liver 
cirrhosis leading to inflammation, regeneration, and fibrosis. The cycle of 
regeneration followed by fibrosis may lead to cirrhosis because fibrosis disrupts 
normal cell-cell and cell-matrix interactions leading to loss of growth control. During 
fibrosis, liver cells regenerate in an abnormal pattern, primarily forming nodules that 
are surrounded by fibrous tissue. Grossly abnormal liver architecture can lead to 
decreased blood flow to and through the liver. This induces oxidative stress in liver 
that may result in DNA damage. Besides, the repetitive cycles of inflammation and 
necrosis contributes to loss of cell growth control (Röcken and Carl-McGrath, 2001; 
http://cpmcnet.columbia.edu/dept/gi/cirrhosis.html; http://www.cancer.gov/ 
cancerinfo/pdq/treatment/adult-primary-liver/healthprofessional/).  
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It should be emphasized that 6D5 stains tumor cells not in all cases. Presumably, the 
underlying reason is related to the molecular differentiation status of the cancerous 
cells. Additionally, the gender of the patients and gross pathological differences that 
may be present in the livers, which our biopsy specimens are sampled, may 
contribute to the molecular differences between the tumor pathology of the 
individual patients. Those gross pathological differences may involve presence of 
cirrhosis, presence of fibrosis, underlying genetic diseases (e.g., hemochromatosis, 
Wilson’s disease, hereditary tyrosinemia, type 1 glycogen storage disease), and liver 
localization of the tumor as primary or secondary site.  
 
As a conclusion, the outcomes of this study are as follows: 
 
• It appears that there is a differential expression of the proteins, which 6D5 
and 9C11 reacts with, specific to tissue type of the cell lines. 
 
• None of 6D5 or 9C11 antibodies react with protein extracts of FLC4, CAMA-
1, LS411N, COS-7 and Sp2 cell lines. 
 
• FLC4, CAMA-1 and LS411N are the only human cancer cell lines that both 
6D5 and 9C11 are not immunoreactive to.  
 
• All but one of the 14 hepatocellular carcinoma cell lines express at least one 
epitope that is recognized by 6D5 or 9C11 antibody under our experimental 
conditions. FLC4 is the only liver cancer cell line that does not express any 
recognizable epitope by 6D5 or 9C11 monoclonal antibody. 
 
• 6D5 does not have cross-species reactivity, whereas 9C11 is immunoreactive 
to IAR 6 and Ankara cell lines leading to cross-species reactivity.   
 
• Band intensities of Western blotting with 6D5 antibody is diverse than that of 
9C11 antibody. 
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• Differential expression pattern of Hep3B-TR cell line from Hep3B in 
Western blotting with 6D5 may be as a result of mutation of TGF- βRII gene 
in Hep3B-TR, leading to resistance of this cell line to growth-inhibitory 
effect of TGF-β. The difference between the banding patterns of Figure 4.1 
and Figure 4.6 most probably results from changing 1X SDS gel loading 
buffer to 2X SDS gel loading buffer to ensure the separation of smear-like 
bands from each other and to clarify the banding pattern. 
 
• The differential banding pattern of MRC-5 may be as a result of fibroblastic 
origin and/or mortal feature of this cell line. In addition, the expression 
profile of MRC-5 may be different from other cell lines because of its 
establishment from fetal lung. 
 
• 9C11 does not stain paraffin-embedded liver cancer tissue samples in 
immunoperoxidase staining contrary to 6D5 antibody. 6D5 stains cancerous 
hepatocytes as well as cirrhotic hepatocytes and cirrhotic bile duct 
epithelium. 
 
 
Further studies with 6D5 and 9C11 antibodies may include Western blotting 
experiments to compare normal (non-cancerous) cell lines with cancerous ones to 
find out whether those antibodies recognize differentially expressed epitopes in 
malignant versus normal cells. Another important point is to question the underlying 
reason in the differential expression pattern of Hep3B and Hep3B-TR isogenic cell 
lines in Western blotting experiments with 6D5. Sugano et al. (2003) underlines that 
increased production of TGF-β is characteristic of HCC implying the resistance to 
autocrine TGF-β. In Hep3B-TR, being resistant to growth-inhibitory effect of TGF-β 
may be leading to deregulation of several proteins including Smad proteins.  
 
Broadening the tissue sample panel for immunohistochemistry studies may 
contribute to the expression profile of the epitopes recognized by 6D5 and 9C11 in 
terms of tissue specificity. Additionally, immunofluorescence studies may reveal the 
cellular localization of the epitopes.  
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For the characterization of the proteins recognized by 6D5 and 9C11, protein 
sequencing is required. With the help of protein sequencing, the banding patterns 
observed in Western blotting experiments may be elucidated and it would be 
revealed if those bands represent the alternatively spliced forms of the proteins. 
Sequencing may also reveal if 6D5 and 9C11 recognize novel proteins or novel 
epitopes of already investigated proteins. Characterization of the targeted epitopes or 
proteins may lead us to have an opinion on the function of those molecules. Another 
contribution of sequencing may be elucidation of value of 6D5 and 9C11 as novel 
tumor markers. When 6D5 and 9C11 are characterized as novel tumor markers, they 
can be used in research and/or for diagnostic, prognostic or therapeutic purposes 
according to the degree of their specificity and informative features. 
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